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Abstract
Membrane transporters are widely recognized for their role in drug disposition in humans.
Differences in drug concentration among individuals for drugs used to treat cardiovascular
diseases, such as statins and ezetimibe, may result from alteration in hepatic and intestinal
transporter function due to genetic, clinical or environmental factors, causing variability in
drug efficacy or toxicity.

The closely related uptake transporters organic anion-transporting polypeptides OATP1B3
and OATP1B1, are expressed in human liver sharing numerous drug substrates, including 3hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, or statins. Recently, a transportdeficient OATP1B1 variant was associated with increased statin exposure and toxicity,
however little is known regarding the functional relevance of genetic variation in OATP1B3.
We assessed OATP1B3 coding sequence and identified novel polymorphisms; two variants
displayed impaired rosuvastatin transport in vitro. OATP1B3 polymorphisms may represent
an unrecognized determinant of statin disposition.
The organic solute transporter (OST) αβ is highly expressed in human ileum and plays a key
role in bile acid transport from the intestinal lumen into portal blood. However, drug
substrates are largely unexplored and the transporter's role in intestinal drug absorption is
unknown. We identified four novel drug substrates of OSTαβ, including rosuvastatin and
atorvastatin, and characterized an OSTβ variant with impaired transport in vitro. Utilizing
biopsy samples, we observed abundant expression in ileum but also duodenum and colon. In
Ostα-/- mice, we demonstrated increased rosuvastatin concentration in plasma and liver
compared to wild-type, further suggesting a role for OSTαβ in drug transport.

Targeted inhibition of intestinal cholesterol transport by ezetimibe is another cholesterollowering approach showing marked interpatient variation, likely resulting from differences in
plasma exposure. Evidence suggests a role of drug transporters in circulating ezetimibe
concentrations. We observed 67-fold variability in ezetimibe concentration, and 140-fold
variability in ezetimibe glucuronide concentration, an active metabolite, in 152 patients
taking ezetimibe. We identified age, BMI, gender and concomitant fenofibrate use as major
iii

determinants of ezetimibe exposure, whereas transporter polymorphisms were less important
predictors; a reduced-function OATP1B3 variant was associated with metabolite-to-parent
ratio but not drug level.

These findings illustrate additional mechanistic insights that show the importance of hepatic
and intestinal membrane transporters to drug disposition.

Keywords
Drug disposition; pharmacogenetics; drug transport; organic anion transporting polypeptides;
organic solute transporter alpha-beta; intestinal absorption; hepatic uptake; statin transport;
ezetimibe; ezetimibe pharmacokinetics

iv

Co-Authorship Statement
Chapter Three:
Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y,
Mizuguchi K, Ho RH, and Kim RB. 2011. Identification of novel functional Organic Aniontransporting Polypeptide 1B3 (OATP1B3) polymorphisms and assessment of substrate
specificity. Pharmacogenetics and Genomics 21:103-114
UIS, RGT and RBK designed the experiments. YM and KM were responsible for mapping of
genetic variants on structural model. UIS, HEM, BL, and RHH conducted the experiments.
UIS, RGT, and RBK analyzed and interpreted the data. UIS wrote the manuscript. RBK, and
RGT were responsible for critical revision of the manuscript. All authors approved the final
version of the manuscript.
Chapter Four:
Schwarz UI, MD, Meyer zu Schwabedissen HE, Yip C, Leon-Ponte M, Leake B, Ho RH,
Urquhart BL, Tirona RG, Haywood J, Dawson PA, and Kim RB. The bile acid transporter
organic solute transporter (OST) αβ is also an intestinal drug transporter. 2012, manuscript in
preparation
UIS, RGT, RBK designed in vitro and in vivo studies. JH and PAD were responsible for
acquisition, analysis, and interpretation of data from mouse studies. BLU obtained intestinal
tissue samples. UIS, HEM, CY, ML-P, RHH and BL were responsible for acquisition of data.
UIS, RGT, RBK, HEM, and ML-P analyzed and interpreted the data. UIS wrote the
manuscript. RBK, RGT and PAD provided feedback on the manuscript.
Chapter Five:
Schwarz UI, DeGorter MK, Tirona RG, Choi Y, Hegele RA, and Kim RB.
Drug transporter pharmacogenetics: implication for ezetimibe drug level. 2012, manuscript
in preparation
UIS, MKD, RAH and RBK designed the study. UIS, MKD, RAH participated in patient
enrolment and data collection. UIS measured ezetimibe concentrations, and MKD performed
genotyping. UIS, RGT, MKD, RAH, YHC, and RBK analyzed and interpreted the data. UIS
wrote the manuscript. MKD, RBK, RGT, and YHC provided feedback on the manuscript.

v

Acknowledgments
I would first like to thank my supervisor Dr. Richard Kim for his support, guidance,
encouragement and friendship over the years. I would also like to thank my advisory
committee, Drs David Freeman, Rommel Tirona, David Bailey, Yun-Hee Choi, and Paul
Dawson for their guidance and constructive criticisms through each stage of my graduate
work.

I am grateful to the past and present members of the Kim Lab. I am thankful to Brenda
Leake, Dr Matilde Leon-Ponte and Linda Asher for expertise and guidance, to Sara Mansell
and Cameron Ross for help with animal work and patient genotyping, and to Julie Brown and
Robin Legan for kind assistance. During the years of my graduate studies I have enjoyed
working with many summer and graduate students as well as postdoctoral fellows providing
in depth discussions, provocative ideas, and true inspiration: Marianne DeGorter, Dr
Henriette Meyer zu Schwabedissen, Dr Wendy Teft, Inna Gong, Cindy Yip, Michael Knauer,
Dr Murray Cutler, and Dr Brad Urquhart.

I had opportunity for fruitful collaborations. It has been a pleasure to work with Dr Robert
Hegele, who enabled and supported the clinical study in his clinic, and I am thankful to
Brooke Kennedy, Nancy Schmidt, and Matthew Ban, who helped with patient recruitment
and sample collection. Dr. Paul Dawson and Jamie Haywood have been instrumental for the
Ostα knockout mouse studies that were performed in Dr. Dawson’s laboratory at Wake
Forest University.

I am blessed to have incredible friends and family, who have been supportive over all these
years and across continents. I would like to sincerely thank my parents for allowing me to
follow a passion for science, my husband for his firm support, and my three children for their
understanding and smiles.

vi

Table of Contents
CERTIFICATE OF EXAMINATION ........................................................................... ii
Abstract .............................................................................................................................. iii
Co-Authorship Statement.................................................................................................... v
Acknowledgments.............................................................................................................. vi
Table of Contents .............................................................................................................. vii
List of Tables ..................................................................................................................... xi
List of Figures ................................................................................................................... xii
List of Appendices ........................................................................................................... xiv
Abbreviations .................................................................................................................... xv
1 INTRODUCTION ......................................................................................................... 1
1.1 Role of membrane transporters in drug disposition ................................................ 2
1.2 Genetic variation in drug transport proteins ........................................................... 7
1.3 Lipid-lowering drug treatment ................................................................................ 9
1.3.1

Statins.......................................................................................................... 9

1.3.2

Ezetimibe .................................................................................................. 12

1.4 References ............................................................................................................. 23
2 SPECIFIC AIMS AND HYPOTHESES ..................................................................... 37
2.1 Specific aim 1 ....................................................................................................... 38
2.2 Specific aim 2 ....................................................................................................... 39
2.3 Specific aim 3 ....................................................................................................... 41
2.4 References ............................................................................................................. 42
3 IDENTIFICATION OF NOVEL FUNCTIONAL ORGANIC ANIONTRANSPORTING POLYPEPTIDE 1B3 (OATP1B3) POLYMORPHISMS AND
ASSESSMENT OF SUBSTRATE SPECIFICITY ..................................................... 44
3.1 Introduction ........................................................................................................... 45
vii

3.2 Materials and methods .......................................................................................... 46
3.2.1

Materials ................................................................................................... 46

3.2.2

Identification of SLCO1B3 polymorphisms and determination of allelic
frequencies ................................................................................................ 47

3.2.3

Variant SLCO1B3 plasmid construction ................................................... 47

3.2.4

Transient transfection and uptake transport assays ................................... 47

3.2.5

OATP1B3 cell surface and total protein expression and structural mapping
................................................................................................................... 48

3.2.6

Statistical analysis ..................................................................................... 49

3.3 Results ................................................................................................................... 49
3.3.1

Polymorphisms in SLCO1B3 and allelic frequency.................................. 49

3.3.2

OATP1B3 is the main CCK8 uptake transporter in liver ......................... 49

3.3.3

Functional analysis of OATP1B3 variants ............................................... 50

3.3.4

Total and cell surface expression of OATP1B3 variants .......................... 51

3.3.5

Amino acid conservation and structural model ........................................ 51

3.3.6

Effect of extracellular pH on CCK8 transport by OATP1B3 His520Pro
variant ....................................................................................................... 52

3.4 Discussion ............................................................................................................. 71
3.5 References ............................................................................................................. 75
4 THE BILE ACID TRANSPORTER ORGANIC SOLUTE TRANSPORTER (OST)
ALPHA-BETA IS ALSO AN INTESTINAL DRUG TRANSPORTER .................... 81
4.1 Introduction ........................................................................................................... 82
4.2 Methods................................................................................................................. 84
4.2.1

Materials ................................................................................................... 84

4.2.2

Wild-type and variant human OSTα and OSTβ plasmid construction ..... 84

4.2.3

Mouse Ostα and Ostβ plasmid construction ............................................. 85

4.2.4

Transport and inhibition studies................................................................ 85

4.2.5

Human samples from intestine, liver and kidney...................................... 86
viii

4.2.6

Real-time PCR .......................................................................................... 86

4.2.7

Western blotting by SDS-PAGE ............................................................... 87

4.2.8

Cell surface expression ............................................................................. 88

4.2.9

Animal experiments .................................................................................. 88

4.2.10 Statistical analysis ..................................................................................... 89
4.3 Results ................................................................................................................... 89
4.3.1

Single nucleotide polymorphisms in OSTα and OSTβ.............................. 89

4.3.2

Novel drug substrates of OSTαβ and reduced uptake by protein variants 90

4.3.3

OSTβ gene variant with reduced cell surface expression ......................... 92

4.3.4

Identification of inhibitors of OSTαβ function ......................................... 92

4.3.5

OSTαβ affects rosuvastatin disposition in knockout mice........................ 92

4.3.6

OSTα protein is highly expressed in human intestine but not detected in
liver ........................................................................................................... 93

4.4 Discussion ........................................................................................................... 106
4.5 References ........................................................................................................... 109
5 DRUG TRANSPORTER PHARMACOGENETICS: IMPLICATION FOR
EZETIMIBE DRUG LEVEL..................................................................................... 113
5.1 Introduction ......................................................................................................... 114
5.2 Methods............................................................................................................... 116
5.2.1

Study subjects and design ....................................................................... 116

5.2.2

DNA extraction and genotyping ............................................................. 116

5.2.3

Quantitative analysis of ezetimibe and its glucuronide metabolite ........ 117

5.2.4

Statistical analysis ................................................................................... 118

5.3 Results ................................................................................................................. 119
5.3.1

Study subjects and demographics ........................................................... 119

5.3.2

Variability in ezetimibe and ezetimibe glucuronide concentration in
plasma ..................................................................................................... 119
ix

5.3.3

Determinants of ezetimibe concentration ............................................... 120

5.3.4

Determinants of ezetimibe glucuronide concentration ........................... 120

5.3.5

Determinants of ezetimibe glucuronide/ ezetimibe ratio ........................ 121

5.3.6

Ezetimibe trough level ............................................................................ 122

5.4 Discussion ........................................................................................................... 133
5.5 References ........................................................................................................... 136
6 DISCUSSION AND CONCLUSIONS ..................................................................... 144
6.1 Summary and discussion..................................................................................... 145
6.1.1

Chapter three ........................................................................................... 145

6.1.2

Chapter four ............................................................................................ 146

6.1.3

Chapter five ............................................................................................. 148

6.2 Therapeutic implications and future directions................................................... 149
6.2.1

Chapter three ........................................................................................... 149

6.2.2

Chapter four ............................................................................................ 150

6.2.3

Chapter five ............................................................................................. 150

6.3 Conclusions ......................................................................................................... 152
6.4 References ........................................................................................................... 153
Appendices ...................................................................................................................... 156
Curriculum Vitae ............................................................................................................ 170

x

List of Tables
Table 1.1 Reported drug interactions studies of ezetimibe using a single and chronic doses of
10mg or 20mg ezetimibe ........................................................................................................ 19
Table 1.2 Potential role of ABC efflux transporters suggested by animal models ................ 21
Table 3.1 Oligonucleotide primer sequences to carry out PCR of the SLCO1B3 coding
region ...................................................................................................................................... 53
Table 3.2 SLCO1B3 gene coding region variants .................................................................. 54
Table 3.3 Allelic and genotype frequencies of non-synonymous SLCO1B3 gene variants
among different ethnic populations ........................................................................................ 55
Table 3.4 Minor Allelic Frequency (%) of functional SLCO1B3 polymorphisms ................ 57
Table 5.1 Genotype frequency of patients (N = 152) .......................................................... 123
Table 5.2 Patient demographics ........................................................................................... 124
Table 5.3 Effects of selected predictors on log ezetimibe concentration in linear regression
............................................................................................................................................... 125
Table 5.4 Effects of selected predictors on log ezetimibe glucuronide concentration in linear
regression .............................................................................................................................. 126
Table 5.5 Effects of selected predictors on log ezetimibe glucuronide/ ezetimibe ratio in
linear regression ( < 24hr post dose) ..................................................................................... 127

xi

List of Figures
Figure 1.1

Overview of hepatic (A) and intestinal (B) transporters involved in drug

disposition in humans ............................................................................................................... 4
Figure 1.2 Intestinal cholesterol absorption pathway and mechanism of ezetimibe-mediated
inhibition. ................................................................................................................................ 14
Figure 1.3 Enterohepatic circulation of ezetimibe and potential role of transporters ............ 18
Figure 3.1

Schematic representation of organic anion-transporting polypeptide 1B3

(OATP1B3) ............................................................................................................................. 59
Figure 3.2 [3H]-CCK8 uptake transport activity (0.1 µM) following transient heterologous
expression in HeLa cells. ........................................................................................................ 61
Figure 3.3 Transport kinetics of organic anion-transporting polypeptide 1B3 (OATP1B3)
following transient heterologous expression in HeLa cells conducted at 5 min at varying
concentrations of CCK8 (1-50 µM). ....................................................................................... 63
Figure 3.4

Rosuvastatin and atorvastatin uptake transport activity (0.1µM) following

transient heterologous expression of organic anion-transporting polypeptide 1B3 (OATP1B3)
in HeLa cells. .......................................................................................................................... 65
Figure 3.5 Total (left panel) and cell surface protein expression (right panel) of organic
anion-transporting polypeptide 1B3 (OATP1B3) variants in comparison to wild type and
vector control lacking any insert. ............................................................................................ 66
Figure 3.6 Organic anion transporting polypeptide 1B3 (OATP1B3) variants V560A and
H520P mapped on to the earlier described structural model of OATP1B3 (23) viewed from
(A) the lateral side and (B) the intracellular side. ................................................................... 68
Figure 3.7 Effect of organic anion-transporting polypeptide 1B3 (OATP1B3) His520 in
comparison to the variant OATP1B3 Pro520 on pH-sensitivity. ........................................... 70

xii

Figure 4.1 Putative secondary structure of OSTα and OSTβ (A) and OSTα and OSTβ amino
acid alignments (B). ................................................................................................................ 95
Figure 4.2 Drug uptake and drug efflux after transient expression of human OSTαβ (wild
type) in HeLa cells. ................................................................................................................. 97
Figure 4.3 Transient expression of human OSTαβ (wild-type and variants) in HeLa cells to
assess drug uptake and transport kinetics. .............................................................................. 99
Figure 4.4 Immunoblot of total cell lysate and cell surface protein after transient expression
of wild-type and variant OSTαβ in HeLa cells. .................................................................... 100
Figure 4.5 Inhibition of OSTαβ-mediated taurocholate uptake by drug compounds. ......... 102
Figure 4.6 Drug uptake by mouse Ostαβ after transient expression in HeLa cells and in situ
transport studies using Ostα-/- mice. .................................................................................... 103
Figure 4.7 Expression of OSTα and OSTβ in intestinal biopsy samples from 8 healthy
patients. ................................................................................................................................. 105
Figure 5.1 Ezetimibe and ezetimibe glucuronide concentration in patients (N = 152) taking
10 or 20 mg daily (A) and in patients taking 10 mg grouped according to time from last dose
(B). ........................................................................................................................................ 128
Figure 5.2 Association of plasma ezetimibe and ezetimibe glucuronide concentration with
demographics (N = 152). ...................................................................................................... 129
Figure 5.3 Correlation between ezetimibe and metabolite concentration (upper panel) and
association of UGT1A1 genotype with ezetimibe glucuronide concentration (lower panel)130
Figure 5.4 Plasma concentration and metabolite-to-parent ratio for study patients (N = 152)
receiving fenofibrate in comparison to patients without concomitant fenofibrate. .............. 131
Figure 5.5 Determinants of therapeutic trough level of total ezetimibe (ezetimibe plus
ezetimibe glucuronide).......................................................................................................... 132

xiii

List of Appendices
Appendix A: Supplemental information, Chapter 4 ............................................................. 157
Appendix B: Ethics approval ................................................................................................ 164
Appendix C: Copyright approval .......................................................................................... 167

xiv

Abbreviations
ABC

ATP-binding cassette

ACAT

acyl-CoA:cholesterol acyltransferase

ANOVA

analysis of variance

ASBT

apical sodium-dependent bile acid cotransporter

ATP

adenosine triphosphate

AUC

area under the curve

BCRP

breast cancer resistance protein

BMI

body mass index

BSEP

bile salt export pump

CCK8

cholecystokinin-8

cDNA

complementary deoxyribonucleic acid

CI

confidence interval

Cmax

maximum plasma concentration

Css

steady state concentration

CT

threshold cycle

CYP

cytochrome P450

DNA

deoxyribonucleic acid

ECL

extracellular loop

EDTA

ethylenediaminetetraacetic acid

ER

endoplasmic reticulum

ERC

endocytic recycling compartment

FXR

Farnesoid X receptor

HEK239

human embryonic kidney 239

HeLa

human cervical carcinoma

HIV

human immunodeficiency virus

HMG-CoA

3-hydroxy-3-methylglutaryl coenzyme A

IS

internal standard

Km

concentration at which half the maximal uptake occurs

LC-MS/MS

liquid chromatography-tandem mass spectrometry

LDL-C

low-density lipoprotein cholesterol
xv

LST

liver-specific transporter

MDR

multidrug resistance

MPA

mycophenolic acid

MPAG

mycophenolic acid glucuronide

mRNA

messenger ribonucleic acid

MRP

multidrug resistance-associated protein

m/z

mass-to-charge ratio

NPC1L1

Niemann-Pick C1 like 1 Protein

NTCP

sodium-dependent taurocholate co-transporting polypeptide

OAT

organic anion transporter

OATP

organic anion transporting polypeptide

OCT

organic cation transporters

ORF

open reading frame

OST

organic solute transporter

PCR

polymerase chain reaction

PEPT

peptide transporter

R2

coefficient of determination

RNA

ribonucleic acid

rpm

revolutions per minute

SD

standard deviation

SDS-PAGE

sodium dodecyl sulfate polyacrylamide gel electrophoresis

SLC

solute carrier

SNP

single nucleotide polymorphism

t1/2

elimination half-life

tmax

time to maximum plasma concentration

TCA

taurocholate acid

UGT

UDP-glucuronosyltransferase

Vmax

maximal velocity (maximum uptake rate)

xvi

1

1

INTRODUCTION
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1.1

Role of membrane transporters in drug disposition

Following oral administration, a drug crosses the intestinal wall, reaches the liver via
portal blood flow and then enters the systemic circulation, which allows the drug to be
distributed to various tissues of the body, including its site of action (1). The drug is
eliminated from the body by metabolism, and by biliary and urinary excretion. During
these processes, a drug molecule passes though several biological membranes. This
movement generally depends on the physicochemical properties of a drug. In addition,
membrane transporters have been more recently reported to play an important role in
facilitating or hindering drug movement (2).

Membrane transporters can be broadly classified as drug uptake (entry from blood into
tissues) and efflux (removal from tissues) transporters, which are located at the apical or
basolateral membrane in polarized cells (3-5). Drug transporters are expressed in organs
such as intestine, liver, or kidney, and are critical for a drug's disposition. Drug
disposition generally refers to all processes involved in absorption, distribution,
metabolism and excretion of drugs in humans. Furthermore, transporters may determine
toxicity; the latter often occurs in concert with phase I and II enzyme-based drug
elimination (6).

Well-known to facilitate the removal of drugs from the body, members of the ATPbinding cassette (ABC) transporter family contribute critically to their bioavailability,
and thus often control the effects and toxicity of drugs (7) (Figure 1.1).

3

Figure 1.1 Overview of hepatic (A) and intestinal (B) transporters involved in drug
disposition in humans. Members of the ATP-binding cassette (ABC) superfamily important
in drug disposition include ABCB1 (also P-glycoprotein, MDR1), ABCG2 (also breast
cancer resistance protein, BCRP), and transporters of the multidrug resistance-associated
protein (MRP;ABCC) family ABCC2 (also MRP2), ABCC3 (also MRP3), and ABCC4 (also
MRP4). Members of the solute carrier (SLC) superfamily include organic anion transporting
polypeptides (OATPs/ SLCO), namely OATP1B1, OATP1B3, OATP1A2 and OATP2B1,
organic cation transporters (OCTs/ SLC22A), namely OCT1 and OCT3, organic anion
transporters (OATs/ SLC22A), and peptide transporter 1 (PEPT1/ SLC15A). Organic solute
transporter (OST) α and β (SLC51A), the apical sodium-dependent bile acid transporter
(ASBT/ SLC10A2), the Na+ taurocholate cotransporting polypeptide (NTCP/ SLC10A1), and
the canalicular bile salt export pump (BSEP/ ABCB11) are predominantly recognized as bile
acid transporters.
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They mediate cellular efflux in an active, ATP dependent manner against concentration
gradients. Based on our present knowledge, ABC efflux transporters play a prominent
role in the oral absorption and elimination of many drugs from the body, among them
ABCB1 (also P-glycoprotein or MDR1/ gene ABCB1)(8), ABCC2 (also multidrug
resistance-associated protein 2, MRP2/ gene ABCC2) (9), and ABCG2 (also breast cancer
resistance protein, BCRP/ gene ABCG2)(10). Drug substrates of the extensively studied
ABCB1 efflux transporter, for example, include clinically important therapeutics such as
the lipid-lowering agents atorvastatin and rosuvastatin, the cardiac glycoside digoxin, the
anticancer agents docetaxel and irinotecan, the HIV protease inhibitors indinavir and
ritonavir, the immunosuppressants cyclosporine A and tacrolimus, and the antibiotic
erythromycin (11). Expressed at the apical membrane of enterocytes (luminal) and
hepatocytes (canalicular, Figure 1.1), these ABC carriers can reduce bioavailability of
orally administered drugs by direct secretion back into the intestinal lumen or by rapid
hepatic elimination via bile. Lack or inhibition of these intestinal or hepatic ABC
transporters results in enhanced drug absorption into the portal vein, and may decrease
biliary secretion, resulting in higher systemic blood and organ levels (12). In contrast to
the aforementioned efflux transporters, ABCC3 (gene ABCC3) localizes to the
basolateral membrane of enterocytes, hepatocytes, and cholangiocytes. Its substrate
specificity is characterized by its preference for glucuronidated compounds including
morphine-3-glucuronide, etoposide-glucuronide, and estradiol-17β-glucuronide (13).

Another important group of transport proteins able to influence drug disposition (Figure
1.1) are the organic anion transporting polypeptides (OATPs) belonging to the family of
membrane solute carriers (solute carrier OATP subfamily/ gene SLCO) (14-16). They are
characteristically known for their sodium-independent transport of substrates with broad
specificity, and play important roles in determining intestinal drug absorption, hepatic
and renal clearance and tissue distribution of endogenous and exogenous substrates
including numerous drugs, bile salts, steroid conjugates, oligopeptides and thyroid
hormones (17). Two important members of this family, OATP1B1 and OATP1B3, are
abundantly expressed in the human liver, where they localize to the basolateral
membrane. Both transporters belong to the same subfamily and share a broad spectrum of
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drug substrates such as the lipid-altering agents, rosuvastatin and atorvastatin (18-19),
and the anticancer agent, methotrexate (20), whereas only OATP1B3 transports the
anticancer agents paclitaxel and docetaxel (21) and the angiotensin II receptor antagonist,
telmisartan (22). They are involved in the uptake of drugs and their conjugates from the
portal blood into the hepatocytes, thereby facilitating their clearance from the body. The
other OATP member expressed at the basolateral membrane of human hepatocytes,
OATP2B1, is also expressed on the apical membrane of enterocytes (23), likely
mediating intestinal uptake of its substrates, for example, the leukotriene receptor
antagonist montelukast (24).

A unique transporter that differs in its amino acid sequence from other previously
identified solute carrier gene family members is the organic solute transporter OSTOST (also OST, gene SLC51) (25-26), a transporter composed of two distinct
proteins called OST and OST. OSTαβ is abundantly expressed at the basolateral
plasma membrane of ileocytes, mediates the intestinal uptake of bile acids into the portal
circulation. In addition to the ileum, OSTαβ is also expressed at other tissue sites,
including the basolateral membranes of cholangiocytes and renal proximal tubular cells.
OST transport activity requires the expression and heterodimerization of both subunits,
OSTα and OSTβ, and although encoded on two different chromosomes, their intestinal
expression appears to be coordinately regulated (27-28). Current knowledge supports a
major role of OSTαβ in the enterohepatic bile acid circulation minimizing fecal and
urinary bile acid loss as well as cytotoxic effects of bile acids due to their limitation from
intestinal and hepatobiliary compartments. Unlike other dedicated bile acid carriers,
preliminary data suggest it may be also capable of drug transport, and its expression in
intestine is not limited to ileocytes (27, 29-30).
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1.2

Genetic variation in drug transport proteins

Altered transporter function, whether due to genetic polymorphisms, drug-drug
interactions, or environmental factors, has been reported to affect drug exposure, and in
many cases, drug efficacy or toxicity in vivo.

Pharmacogenetics of drugs involves the study of the effect of genetic polymorphisms on
response to drugs or "the right drug at the right dose for the right person". Many transport
proteins were found to be polymorphic, and underlying genetic variants are now
recognized for their contribution to interindividual variation in plasma drug
concentrations (5, 11, 31-33). Pharmacokinetics describes the concentration of a drug in
body compartments over time, while pharmacodynamics depicts the pharmacological
response in relation to drug concentration. The immediate consequence of a genetic
polymorphism of a transport protein, which may change its activity or expression, is
generally pharmacokinetic, however the resulting alteration in tissue distribution may
affect the drug’s ability to exert its pharmacodynamic effect, or predispose the patient to
adverse effects.

Genetic variation in genes encoding OATP family members has been reported to
contribute to interindividual differences in the exposure of many clinically relevant drugs
(34-36). Previously, polymorphisms of the SLCO1B1 gene encoding the liver-specific
OATP1B1 protein were identified with significant loss of transport activity (37). Among
those, the extensively studied SLCO1B1 variant c.521T>C (Val174Ala) was shown to be
associated with increased plasma levels of various 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase inhibitors, including rosuvastatin, atorvastatin and pravastatin
(38-39), as well as statin-induced muscle toxicity (40). In contrast, there appears to be
only limited information about genetic variation encoding the closely related hepatic
uptake transporter, OATP1B3. Polymorphisms in the SLCO1B3 gene have been
identified.

Predominantly

two

common

non-synonymous

single

nucleotide

polymorphisms (SNPs), SLCO1B3 c.334T>G (Ser112Ala) and c.699G>A (Met233Ile),
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have been assessed for transport activity (41), but evidence for their clinical importance is
less clear than for SLCO1B1. Recent findings suggest that SLCO1B3 c.334T>G and
c.699G>A influences the pharmacokinetic profile of a newly identified substrate,
mycophenolic acid glucuronide (MPAG), a metabolite of the immunosuppressant
mycophenolic acid (MPA) (42-43). The presence of other yet unidentified SLCO1B3
coding region variants has been proposed, which may affect OATP1B3 transport activity.

Common impaired-function polymorphisms have been also identified in genes of the
ABC efflux carriers such as ABCB1, ABCG2, and ABCC2 with implications for drug
treatment. Among those, ABCB1 is highly polymorphic, although the in vivo role of its
polymorphisms has not been consistently demonstrated (44-46). For example, the
synonymous ABCB1 c.3435C>T variant (Ile1145Ile), reported to cause altered drug and
inhibitor interactions in vitro (47), has been evaluated in numerous studies and linked to
altered transporter function, but the data are conflicting (44, 48). Different experimental
conditions, inadequate samples size, or heterogeneity of the population studied with
confounders such as co-morbidity and co-medication with ABCB1 inhibitors or inducers
may be potential reasons. As well, the interplay of various drug efflux and uptake
transporters or drug metabolizing enzymes with overlapping substrate specificities may
be causative. Studies with larger sample size, more detailed genetic information such as
complex haplotypes but also improved study designs including utilisation of prospective
cohorts, control for stratification (or limitation to one ethnicity), screening for genotyping
error, correction for multiple testing and control for confounders are warranted to clarify
the clinical relevance of ABCB1 polymorphisms in future association studies (46).
Genetic variants have been also reported in ABCG2, another important efflux transporter.
The loss-of-function ABCG2 c.421C>A (Gln141Lys) has been associated with the drug
disposition of various statins as well as the anti-inflammatory drug sulfasalazine (49-50).
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1.3

Lipid-lowering drug treatment

Over the past decades, much progress has been made in the understanding and treatment
of blood lipid abnormalities. Lipid-lowering drugs, particularly HMG-CoA reductase
inhibitors, are widely used to reduce cardiovascular events and death (51-52). In addition,
cholesterol absorption inhibitors such as ezetimibe, fibric acid derivatives, and bile acid
sequestrants are prescribed as lipid-lowering therapeutics in certain clinical conditions.

1.3.1

Statins

Statins are highly effective drugs in the treatment of hypercholesterolemia and proven to
improve cardiovascular disease outcomes. They inhibit hepatic HMG-CoA reductase, a
key enzyme in cholesterol biosynthesis, through a competitive inhibition mechanism
thereby lowering low-density lipoprotein cholesterol (LDL-C) (53).

In general, the currently used statins are well-tolerated and have a good safety profile
(54). However, 10-15% of patients complain from muscle pain or weakness (51, 55). In
rare cases (0.01%), rhabdomyolysis may occur, a life-threatening form of muscle injury
(56). Skeletal side effects are thought to be associated with statin dose and plasma
concentration (57-59), however there exists considerable interindividual variation in the
pharmacokinetic profile of statins, making it very challenging to predict which
individuals will suffer from these side effects.

1.3.1.1

Statin pharmacokinetics

Statins differ in their pharmacokinetic properties (60-62). The main clearance mechanism
for more lipophilic statins is oxidative biotransformation, whereas more hydrophilic
statins such as pravastatin and rosuvastatin do not undergo significant metabolism, and
are excreted mainly unchanged. Cytochrome P450 (CYP) 3A4 is likely the most
important CYP enzyme in the elimination of lipophilic statins including lovastatin,
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simvastatin, and atorvastatin. Accordingly, concomitant use of potent CYP3A4 inhibitors
can increase the plasma concentration of statins dramatically. Atorvastatin exposure was
augmented 2-4-fold after coadminstration of the antifungal itraconazole, and 4-fold after
coadministration of the macrolide antibiotic clarithromycin. The consumption of
grapefruit juice was reported to increase plasma exposure of simvastatin 2-10-fold, and of
atorvastatin 1-4-fold. On the other hand, inducers of CYP enzymes such as rifampin, can
greatly decrease the exposure of statin compounds, in case of atorvastatin by 80%, and
thus may limit the lipid-lowering effect in a patient.

Membrane transporters appear to have significant effects on the pharmacokinetics of
most statins, demonstrated by marked changes in plasma drug levels following
transporter inhibition or due to presence of impaired-function polymorphisms (62-63).
The liver-specific membrane transporter OATP1B1 is thought to be important for statin
uptake into the liver. In addition, other uptake carriers are capable of statin transport such
as OATP1B3 and OATP2B1, as well as the efflux carriers ABCB1, ABCG2, and
ABCC2. Rosuvastatin, for example has been reported to be a substrate of multiple OATP
family members, such as OATP1B1, OATP1B3, OATP2B1 and OATP1A2, as well as
the efflux carriers ABCG2 and ABCB1 (18, 64). The more lipophilic atorvastatin was
shown to be subject to OATP1B1, ABCG2 and ABCB1 transport. Importantly, many
inhibitors of ABCB1 or OATP1B1 also inhibit CYP3A4 metabolism, for example
cyclosporine (62). Concomitant use of cyclosporine with atorvastatin, a shared substrate
of CYP3A4, OATP1B1 and ABCB1, resulted in a significant 6- to 15-fold increase in the
statins' AUC, and may increase myopathy risk, particularly in transplant patients who
often require lipid-lowering therapy with statins. Similarly, gemfibrozil and its
glucuronide inhibit OATP1B1- and OATP2B1-mediated statin uptake into the liver, but
are also known inhibitors of CYP2C8. Thus, gemfibrozil may affect the exposure of all
"transporter-dependent" statins including cerivastatin, atorvastatin, pravastatin, and
rosuvastatin.

In conclusion, systemic use of a potent CYP3A4 inhibitor with statins that are substrate
drugs carries an increased risk for the patient to develop muscle toxicity, particularly if
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high statin doses are used or if certain pharmacogenetic factors are present (detailed
below). As well, inhibitors of hepatic statin uptake transporters may increase their plasma
concentration while entry into the liver, the site of therapeutic action, is reduced, thus
likely affecting the benefit-to-risk ratio of those statins.

1.3.1.2

Transporter polymorphisms and statin muscle toxicity

Increased systemic exposure is thought to be one of the risk factors for muscle toxicity, a
common side effect of statin therapy (57-59). Pharmacokinetic studies in healthy subjects
have shown that reduced-function SLCO1B1 polymorphisms, particularly c.521T>C,
increased the plasma concentration for almost all statins, including rosuvastatin,
atorvastatin, simvastatin, and pravastatin (5, 63). In a genome wide association study, this
variant has been recently reported as the most important predictor of myopathy in
patients on high doses of simvastatin (40). Subsequently, in a case control study,
SLCO1B1 c.521T>C was found to modestly predict rhabdomyolysis in cerivastatintreated patients (65). Another randomized study in 509 subjects comparing high versus
low dose treatment of atorvastatin, simvastatin, or pravastatin, indicated an association of
the same polymorphism and adverse events including myalgia and creatinine kinase
elevation for the higher dosing regimen (66). In addition to systemic statin concentration,
the local concentration in skeletal muscle tissue may influence myotoxic side effects of
statins. Recently, OATP2B1 was identified as a statin transporter present in muscle
tissue, supporting a potential role for statin entry into the muscle tissue as potential
mechanism of statin-associated muscle toxicity (19).

Compared to OATP1B1, the effect of genetic variation in the related uptake transporter,
OATP1B3, on statin transport is less clear (49). Previously, two common polymorphisms
with substrate-specific effects have been reported, SLCO1B3 c.334T>G and c.699G>A
(41). However, their influence on transport of statin substrates such as rosuvastatin and
atorvastatin has not been studied. Reported and yet unknown genetic variation in the
OATP1B3 exome are thus potential determinants of statin exposure as well as muscle
toxicity.
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1.3.2

Ezetimibe

Despite the proven reduction of cardiovascular risk by statins, a significant number of
statin-treated patients may fail to reach LDL-C goals for various reasons (67), i.e. may
not be able to take a higher statin dose or any statin agent due to safety concerns.
Ezetimibe is a selective inhibitor of intestinal cholesterol absorption (68), thus its
mechanism of action differs from those of other classes of cholesterol-reducing
compounds (69). It has been approved for use as monotherapy and or in combination
with statins for the treatment of primary hypercholesterolemia (70). Ezetimibe exerts its
effect through inhibition of the Niemann-Pick C1 like 1 Protein (NPC1L1) in enterocytes,
a specific transporter essential to the uptake of intestinal cholesterol and phytosterols into
enterocytes (71-74).

1.3.2.1

Intestinal cholesterol uptake and mechanism of ezetimibe
action

In humans, dietary and biliary cholesterol absorption occurs in the small intestine, and
Niemann-Pick C1 like 1 Protein (NPC1L1) was found to be highly expressed on the
apical surface of absorptive enterocytes (73-76). Interestingly, unlike rodents, humans
highly express NPC1L1 in the liver, with small intestine detection levels of NPC1L1
mRNA at less than 5% of the liver expression levels (77-79). In addition to apical surface
localization, the intestinal cholesterol uptake transporter NPC1L1 has been detected in
intracellular compartments, suggesting intracellular trafficking of the cholesterol
transporter, thereby mediating the movement of cholesterol from the brush border
membrane to various cell organelles including the endoplasmic reticulum for
esterification by acyl-CoA:cholesterol acyltransferase (ACAT-2) to cholesteryl esters and
then transfer onto chylomicrons (76, 79-81). Importantly, most recent findings suggest a
new model for NPC1L1-mediated cholesterol uptake by endocytosis (82), where
NPC1L1 protein recycles between the plasma membrane and the endocytic recycling
compartment (Figure 1.2). When the extracellular cholesterol concentration is high,
cholesterol is incorporated into the plasma membrane and is sensed by cell surfacelocalized NPC1L1. NPC1L1 and cholesterol are then internalized together and
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transported along microfilaments to the endocytic recycling compartment in vesicles,
where large amounts of cholesterol and NPC1L1 are stored. When the intracellular
cholesterol level is low, endocytic recycling compartment-localized NPC1L1 moves back
to the plasma membrane along microfilaments in order to absorb cholesterol.
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Figure 1.2 Intestinal
absorption
pathway
and mechanism of ezetimibemediated inhibition.
Biliary and dietary cholesterol from micelles in the intestinal lumen is bound to
Niemann-Pick C1 like 1 Protein (NPC1L1) located in the apical membrane of the
enterocyte. Thereafter, NPC1L1 bond to cholesterol is internalized via endocytosis and
translocated to the endocytic recycling compartment (ERC), where cholesterol is stored.
From the ERC, cholesterol can either traffic to the endoplasmic reticulum (ER) for
esterification via the acyl-coenzyme A:cholesterol acyltransferase (ACAT) and is built
into chylomicrons, or cholesterol can be secreted back into the intestine via the efflux
pump ABCG5-ABCG8. Ezetimibe inhibits endocytosis of NPC1L1 after the latter is
bond to cholesterol, thereby preventing intestinal cholesterol absorption.
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Ezetimibe may act from the intestinal lumen or the intracellular space through binding to
NPC1L1 residing in the plasma membrane of the enterocyte. The drug was shown to
inhibit cholesterol absorption by blocking the internalization of NPC1L1, thereby
preventing intestinal cholesterol absorption (80, 82-83). Furthermore, the drug may
modulate cholesterol secretion into bile via interaction with hepatic NPC1L1 as another
potential site of action (77) (Figure 1.2).

1.3.2.2

Pharmacokinetics and drug disposition of ezetimibe

Most pharmacokinetic information reported derives from healthy volunteer or small
patient populations collected predominantly during Phase I to Phase III clinical studies
using a 10 or 20 mg dose of ezetimibe (70). After oral dosing, ezetimibe undergoes rapid
and almost complete glucuronidation in the intestinal wall to its active metabolite,
ezetimibe glucuronide, which accounts for the majority (90%) of total ezetimibe in
human plasma. UDP glucuronosyltransferases (UGT), UGT1A1 and UGT1A3, and to a
smaller extent, UGT2B15, have been reported to mediate the glucuronidation of
ezetimibe to its glucuronide metabolite (84-85). The mean time to maximum
concentration (tmax) for ezetimibe glucuronide has been reported 1 and 2 hours from drug
intake, whereas the parent compound appears more slowly in plasma between 4 and 8
hours. Elimination of ezetimibe occurs predominantly via biliary secretion (80% of the
administered dose, 69% as ezetimibe), and approximately 20% of the dose undergoes an
enterohepatic cycling following reabsorption in the small and large intestine (86-87). In
addition, about 11% of the administered dose is renally excreted (9% as ezetimibe
glucuronide). Following repeated oral dosing, elimination occurs slowly with an
estimated terminal elimination half-life (t1/2β) of 16 to 31 hours, and steady state
concentration (Css) is reached after approximately 10 days if administered once daily.
Ezetimibe is not metabolized by CYP enzymes, thus potent CYP inducers or inhibitors
are not likely to alter its plasma concentration (70, 87).

Numerous pharmacokinetic studies suggest highly variable plasma exposure of ezetimibe
(70). Drug exposure, determined as area under the plasma concentration-time-curve
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(AUC), has been reported with variation coefficients ranging from 30% to 63%, however,
predictors of this interindividual variability are presently not well understood. The effect
of demographic and clinical parameters on ezetimibe exposure has been predominantly
assessed in small populations of healthy and patient subjects. Total ezetimibe plasma
concentration was shown to be influenced by age (2-fold increase in the elderly), gender
(20% increase in women), and renal disease (50% increase in renally impaired patients).
Importantly, patients with moderate or severe liver disease showed a substantial 3.5 to
4.2-fold increase of total ezetimibe exposure, and use of ezetimibe is not recommended in
these patients.

1.3.2.3

Interindividual variation in LDL-lowering response to
ezetimibe

The lipid-lowering response of ezetimibe correlates well with dose and plasma
concentration (70, 86). The recommended 10 mg daily dose of ezetimibe results in an
average LDL-C reduction of 20% to 25%, alone or in combination with statins (88-91).
Nevertheless, marked interpatient variation has been observed with respect to its LDL-C
lowering ranging from no response to a marked decrease of 70% compared to
pretreatment values (92-93). Variability in pharmacodynamic response may be caused by
factors affecting the exposure of the drug (ezetimibe concentration) or factors affecting
the drug target. Recently, common haplotypes in the gene encoding the intestinal
cholesterol transporter, NPC1L1, have been reported to determine the LDL-C lowering
response to ezetimibe (93). Defined on three common polymorphisms, variant carriers
(HT2) were observed to respond better to ezetimibe (35% LDL-C reduction) compared to
wild type carriers (HT1) with a 20% to 25% response. In addition, two rare NPC1L1
mutations were identified in two non-responders of ezetimibe (94). On the other hand,
recent evidence suggests potential involvement of membrane transport proteins affecting
the circulating ezetimibe concentration.
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1.3.2.4

Intestinal and hepatic transporters in ezetimibe disposition

Clinical drug interaction studies with known transport inhibitors such as cyclosporine,
fibric acid derivatives, the antibiotic rifampicin, and statins support the notion that
ezetimibe and/or its glucuronide metabolite are substrates of intestinal and hepatic
transporters (Table 1.1, Figure 1.3). This is further supported by preliminary results from
cell-based studies (95-96) as well as data from genetically modified animals (Table 1.2).
Previously, ezetimibe glucuronide was shown to be a substrate of OATP1B1 but not
OATP1B3 in uptake studies using transfected HEK239 cells (96). Initial in vitro
screening results from our laboratory (unpublished data) suggested ezetimibe glucuronide
is a substrate of OATP1B3, a hepatic carrier that shares much of the structure and
substrate specificity of OATP1B1 (14). Regarding the role of ABC efflux transporters in
ezetimibe exposure, a more than 2-fold higher ezetimibe glucuronide concentration has
been observed in serum and liver of mice lacking Abcb1 compared to wild type, as well
as 2-fold higher hepatic ezetimibe levels (97). In addition, a role of Abcg2, Abcc2 or
Abcc3 in the pharmacokinetics of ezetimibe glucuronide has been established in various
models of transporter deficient mice (98) and Abcc2 deficient rats (99) (Table 1.2).
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Figure 1.3 Enterohepatic circulation of ezetimibe and potential role of transporters
After oral administration, ezetimibe is absorbed in the intestine via a yet unknown
mechanism (passive diffusion or active transport?). In the enterocyte, it is extensively
metabolized by UGT1A1 to its active metabolite ezetimibe glucuronide. Intracellular
ezetimibe and glucuronide metabolite is then either secreted into the portal blood
(transporter-mediated?), or back into the intestinal lumen via the apical efflux carriers
ABCB1 and ABCC2. Ezetimibe glucuronide and/or ezetimibe enter the liver via the
uptake transporters OATP1B3 and OATP1B3, and are secreted into bile via the efflux
carriers ABCB1 and ABCC2. The drug may be reabsorbed in its glucuronide form by
OATP2B1, or deconjugated to ezetimibe by bacteria in the large intestine to be
reabsorbed or excreted.
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Table 1.1 Reported drug interactions studies of ezetimibe using a single and chronic
doses of 10mg or 20mg ezetimibe
Coadministered
drug

fenofibratea
(1x145 mg)

Effect on
transporter

Inhibitor of
ABCB1 &
OATP1B1

fenofibrateb

Population
studied

Exposure of
ezetimibec

Exposure of
coadministered
drug

Ref

Healthy
subjects
(N=18)

AUC E by 43%,
AUC G by 48%

=

(103) (104)

Patients
(N=32)

 Cmax total E 64%,

=

(105)

=

(106)

 AUC total E 3.4-fold

n.d.

(107)

=

=

(70)

=

=

(108)

=

=

(70)

AUC total E 48%

(14x200 mg)

gemfibrozilb

Inhibitor of
OATP1B1,
OATP2B1, &
OATP1B3;
ABCC2
substrate

Healthy
subjects
(N=12)

steady-state
cyclosporinea

Inhibitor of
OATP1B1,
ABCB1, &
ABCC2

Renal
transplant
patients

pitavastinb

OATP1B1,
OATP2B1,
OATP1B3,
ABCG2,
ABCC2, &
ABCB1
substrate

Healthy
subjects

OATP1B1,
OATP2B1,
OATP1B3, &
OATP1A2
substrate

Healthy
subjects

OATP1B1
substrate

Healthy
subjects

(7x1200 mg)

(7x2 mg)

rosuvastatinb
(14x10 mg)

pravastatinb
(14x20mg)

 AUC E 1.4-fold,
 AUC total E 1.7-fold

(N=18)

(N=12)
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fluvastatinb
(14x20 mg)

OATP1B1,
OATP2B1, &
OATP1B3
substrate

lovastatinb

Healthy
subjects

=

 AUC

(109)

 AUC total E

=

(70)

=

=

(110)

n.s. (no details
published)

=

(70)

 AUC E 2.3-fold,

n.d.

(95)

n.d.

(111)

(N=32)
Healthy
subjects

(7x20 mg)

1.25-fold (n.s.)

lovastatinb

Healthy
subjects

(7x20 mg)
(N=18)
digoxinb

ABCB1
substrate

Healthy
subjects

(1x0.5 mg)
(N=12)
rifampicina
(8x600 mg)

Inducer of
ABCC2, &
ABCB2 ;
inhibitor of
ABCC2,
ABCB1, &
OATPs

rifampicina

Healthy
subjects

 AUC G 2.8-fold
(N=12)

Healthy
subjects

= AUC E,
AUC G 2-fold

(1x600 mg)
(N=8)
a

single ezetimibe dose;

b

chronic ezetimibe dosing;

c

E, ezetimibe; G ezetimibe glucuronide; total E, total ezetimibe (sum of parent and metabolite);

AUC, area under the curve; Cmax, maxium plasma concentration; , decreased exposure; , increased
exposure; =, exposure unchanged; n.d., not determined
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Table 1.2 Potential role of ABC efflux transporters suggested by animal models
Species

Mouse model

Ezetimibe

Ezetimibe gluc

studied

(gene knockout)

KO versus WT

KO versus WT

Rat

Mouse

Abcc2-/-

Mdr1a/1b -/-

 plasma [C] (2.9-fold);

plasma [C] (8.5-fold);

 fecal excretion

 renal excretion

= plasma [C] (1.7-fold ,

 plasma [C] (2.7-

n.s.);

fold);

liver [C] (2.1-fold);
= fecal excretion (1.8-fold

Mouse

Abcc2-/-

 liver [C] (2.5 fold);

, n.s.)

 renal excretion

n.d.

 biliary excretion
(1.8-fold);
 liver [C] (29-fold)

Mouse

Abcg2-/-

n.d.

= biliary excretion and
= liver [C]

Mouse

Abcg2-/- and
Abcc2-/-

n.d.

 biliary excretion (40fold);
 liver [C] (70-fold);
 plasma [C] (270fold)

[C], concentration; KO, knockout; WT, wild type; n.d., not determined; n.s., not significant.
References: (97-99)
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1.3.2.5

Pharmacogenetics and ezetimibe drug exposure

Polymorphisms in drug transporter genes belonging to the ABC efflux carrier family and
the OATP uptake carrier family have been reported to affect the pharmacokinetics of
many clinically relevant drugs (5). Despite the current evidence for involvement of
intestinal and hepatic transporters from in vitro and animal model data, little is known
about the relationship between drug transporter polymorphisms and plasma ezetimibe
concentration in humans. A pharmacokinetic pilot study compared plasma levels in a
carrier for the SLCO1B1 wild type allele (*1a/*1a) and a carrier heterozygous for the
impaired-function SLCO1B1 *15 allele (388AG/521TC) after a single oral dose of 20 mg
ezetimibe (100). Compared to wild-type, the *15 variant carrier was shown to have 3-fold
higher exposure (AUC) of ezetimibe glucuronide, but also a two-fold increased ezetimibe
exposure. In contrast, in another study in 35 healthy volunteers, AUC of ezetimibe and
ezetimibe glucuronide did not significantly differ between SLCO1B1 wild type and
homozygous carriers of SLCO1B1*15 as well as heterozygous carriers of another
decreased-function variant, SLCO1B1*5 (96). The effect of ABC efflux transporter
polymorphisms on ezetimibe pharmacokinetics has not been assessed in vivo.

In addition, UGT1A1, an important phase II drug-metabolizing enzyme that was shown
to be responsible for the intestinal glucuronidation of ezetimibe to its active metabolite, is
also polymorphic (101). The extensively studied common variant allele UGT1A1*28
contains 7 promoter TA repeats (TA)7 compared to wild type carriers (*1) with 6 TA
repeats (TA)6, and results in impaired expression and function of the enzyme.
UGT1A1*28 was found to determine the exposure of other drug substrates such as SN38, the active metabolite of the topoisomerase inhibitor irinotecan, and was associated
with more frequently occurring side effects of the drug (102). The role of UGT1A1*28 in
ezetimibe glucuronide exposure is presently not known.

Taken together, pharmacogenetic markers such as drug transporter and drug-metabolizing
enzyme polymorphisms may help elucidate the interindividual variability observed in
ezetimibe and ezetimibe glucuronide exposure in humans (Figure 1.3).
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2.1

Specific aim 1

To identify genetic variation in SLCO1B3 encoding the hepatic transporter
OATP1B3, and to examine the influence of genetic polymorphisms of OATP1B3 on
in vitro transport of lipid-lowering drugs

The uptake transporter organic anion transporting polypeptide 1B3 (OATP1B3, gene
SLCO1B3) is abundantly expressed in human liver and is involved in hepatic clearance of
various xenobiotics including statins (1). Yet unidentified OATP1B3 polymorphisms in
the coding region of SLCO1B3 may be of functional relevance, and may therefore affect
substrate drug disposition in vivo.

We hypothesized that novel loss-of-function polymorphisms in OATP1B3 exist and
that they affect the intracellular uptake of the 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors rosuvastatin and atorvastatin, two
known OATP1B3 substrates, in a cell-based activity assay. To test this hypothesis we
first assessed the SLCO1B3 coding region in ethnically diverse individuals by sequencing
or temperature-dependent capillary electrophoresis. According to the identified
polymorphisms, variant SLCO1B3 expression plasmids were created. After transient
expression in HeLa cells, OATP1B3 transporter variants were evaluated for their effects
on uptake activity using the OATP1B3-specific substrate cholecystokinin-8 (CCK8), and
subsequently using rosuvastatin and atorvastatin. Furthermore, cell surface expression of
OATP1B3 variants was assessed and variants mapped on a structural model of
OATP1B3.

As described in chapter 3, we identified six non-synonymous polymorphisms including
novel variants SLCO1B3 c.439A>G (Thr147Ala), c.767G>C (Gly256Ala), c.1559A>C
(His520Pro) and c.1679T>C (Val560Ala). Allelic frequencies occurred ethnicitydependent, with the latter observed only in African Americans (3.6%). We showed that
after expression in HeLa cells, OATP1B3 His520Pro, Val560Ala, and previously
described Met233Ile or Met233Ile_Ser112Ala haplotype demonstrated decreased uptake
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activity for CCK8 and rosuvastatin, but not atorvastatin, compared to wild type. Kinetic
CCK8 analysis further revealed reduced Vmax (maximum uptake rate) but no marked
change of Km (concentration at which half of the maximal uptake occurs). We determined
that His520Pro and Val560Ala exhibit decreased total and plasma membrane protein
expression, suggesting that the observed alterations in transport activity, in part, may
result from decreased total protein and, in some cases, cell surface targeting of the variant
OATP1B3. Val560 mapped onto a structural model of OATP1B3 revealed this is a key
region for substrate–transporter interaction.

2.2

Specific aim 2

To assess drug transport activity, intestinal expression, and functional gene
polymorphisms of the bile acid transporter OSTαβ
The bidirectional heteromeric organic solute transporter (OST) αβ is highly expressed in
human ileum and plays a major role in the enterohepatic circulation of bile acids (2), but
little is known about its ability to transport xenobiotics or the extent of intersubject
variation in its expression in different parts of the human intestine.

The overall hypothesis is that OSTβ is a transporter of important relevance to
intestinal absorption of drugs including lipid-lowering agents.
Specifically, we hypothesized that 1. OSTβ transports drugs, 2. there is considerable
OST and OSTβ expression along the small and large intestine in humans with high
interindividual variability, 3. there are genetic polymorphisms in OSTα and OSTβ genes
with functional impact, and 4. there is in vivo relevance of intestinal OSTβ transport for
drug disposition. To address these hypotheses, we initially screened 18 radiolabeled
drugs for OSTαβ-mediated transport activity in vitro. Using a single time point and dose,
we identified several novel drug substrates that we further characterized regarding their
transport characteristics using transient expression of human OSTα and OSTβ in HeLa
cells. In biopsy samples of 8 healthy patients, we assessed OSTα and OSTβ expression in
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duodenum, ileum, and colon, compared to liver and kidney by real-time PCR (relative
quantification of gene expression; 2-CT method) and Western blotting. To study
potential consequences of gene polymorphisms in OSTα and OSTβ, we selected two
common non-synonymous SNPs reported in the dbSNP database with confirmed
frequency

as

determined

by

(http://hapmap.ncbi.nlm.nih.gov/)

large

genotyping

and

the

projects

such

1000Genomes

as

HapMap
project

(http://www.1000genomes.org/), namely OSTα c.604G>A (Val202Ile; rs939885) and
OSTβ c.362C>T (Pro121Leu; rs75962063). We then evaluated the functional effect of the
two variant proteins on OSTαβ transport activity in vitro by measurement of intracellular
uptake and concentration-dependent uptake kinetics in comparison to wild type. In
addition we assessed a potential in vivo effect of Ostαβ to rosuvastatin disposition using
an Ostα-/- mouse model.

As described in chapter 4, we demonstrated that the lipid-lowering drugs rosuvastatin and
atorvastatin, as well as the chemotherapeutic docetaxel and the anti-inflammatory agent
sulfasalazine are novel substrates of OSTαβ. We further showed that OSTαβ-mediated
bile acid uptake is inhibited by the cholesterol absorption inhibitor ezetimibe as well as
sulfasalazine. We demonstrated that OSTβ Pro121Leu leads to moderate impairment of
transport activity in vitro, whereas OSTα Val202Ile had little effect. OSTβ Pro121Leu
resulted in decreased OSTβ surface expression in vitro suggesting cell surface trafficking
as a potential underlying mechanism for the observed functional effect. Using intestinal
biopsy samples we confirmed that OSTα and OSTβ mRNA is highly abundant in small
and large intestine with moderate variability, with a positive correlation between OSTα
and OSTβ subunits. In addition, we show that regional OSTα protein expression
corresponded largely with that of OSTα mRNA expression, with highest expression in
ileocytes, followed by colonocytes and duodenal enterocytes. Despite abundant mRNA,
OSTα protein was not detected in human liver. Using a genetically modified mouse
model we observed a higher concentration of the lipid-lowering agent rosuvastatin in
plasma and liver of transporter lacking animals (Ostα-/-) relative to wild type after
intestinal drug administration.
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2.3

Specific aim 3

To assess drug transporter polymorphisms and their implication for ezetimibe drug
level

Lipid-lowering agents are frequently prescribed to lower LDL cholesterol (LDL-C) and
to reduce cardiovascular disease risk. Ezetimibe is a selective inhibitor of intestinal
cholesterol absorption, and reduces LDL-C alone or in combination with statin therapy
(3). Marked interpatient variation has been observed with respect to its LDL cholesterol
lowering response ranging from no response to a marked decrease of 70% compared to
pretreatment values (4). Variability in pharmacodynamic response may be caused by
factors affecting the drug target or the exposure of the drug (ezetimibe concentration).
Reported drug interactions suggest a role of uptake and efflux drug transporters in the
circulating ezetimibe concentration. Preliminary results from cell-based studies as well as
data from genetically modified animals further support that ezetimibe and/or its
glucuronide metabolite are substrates of the drug uptake facilitating liver-specific organic
anion polypeptide (OATP) 1B1 as well as efflux transporters of the ATP-binding cassette
(ABC) family such as ABCC2, ABCG2, and ABCB1. Common genetic polymorphisms
in these transport proteins are known to contribute to interindividual variation in the
exposure of numerous drugs, including other lipid-lowering agents such as statins. In
addition, concomitant medication and demographic factors may be of importance.

We hypothesized that common polymorphisms of uptake and efflux transporters
located in the human intestine and liver determine interpatient variability in the
systemic exposure of ezetimibe and its active metabolite, ezetimibe glucuronide. To
test this hypothesis, we assessed differences in plasma ezetimibe and ezetimibe
glucuronide concentration in a large patient population. We prospectively enrolled 152
patients with dyslipidemia aged 18 years and older who were chronically taking a daily
dose of 10 mg or 20 mg ezetimibe. During a regular clinic visit, a single blood sample
was drawn, and a detailed medical history obtained. DNA was isolated from blood
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samples to test for genetic variants. Drug concentration was measured in plasma using
liquid chromatography-tandem mass spectrometry (LC-MS/MS).

As described in chapter 5, we demonstrated up to 67-fold variability in ezetimibe
concentration, and 140-fold variability in ezetimibe glucuronide concentration. We
identified age, BMI, and gender as well as concomitant lipid-lowering therapy with
fenofibrate as major determinants of ezetimibe exposure. Uptake and efflux transporter
polymorphisms and co-prescribed statins including rosuvastatin and atorvastatin were
less important predictors. Overall, demographics, comedication and pharmacogenetic
factors explained 29% to 39% of this large interpatient variability in drug concentrations.
Using the best fit multivariate regression model derived from our data set, we further
showed that the lower 25th percentile of the predicted trough level of total ezetimibe
concentration in plasma (ezetimibe plus ezetimibe glucuronide) is 16.7 ng/mL in patients
taking a 10 mg dose. With respect to a proposed target trough concentration of 15 ng/mL
total ezetimibe required to achieve a greater than 15% reduction in LDL cholesterol, up
to 25% of patients are not treated to the maximal LDL-C lowering response.
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3.1

Introduction

The human organic anion-transporting polypeptide (OATP) 1B3 (also OATP-8 or LST-2,
gene name SLCO1B3) belongs to a liver-enriched OATP subfamily that is predominantly
expressed on the basolateral membrane domain of hepatocytes. OATP1B3 shares 80%
sequence identity with the other member of this subfamily, human OATP1B1 (also
OATP-C or LST-1, gene name SLCO1B1) (1). In contrast to OATP1B1, OATP1B3 has
also shown to be expressed in cancer tissues (2-3). Both transporters share a broad
spectrum of drug substrates including the 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins), rosuvastatin and atorvastatin (4-5); the anticancer agent,
methotrexate (3), the angiotensin II receptor antagonist, olmesartan (6); and the antibiotic
rifampicin (7). However, OATP1B3 but not OATP1B1 has been shown capable of
mediating the cellular uptake for drugs such as the angiotensin II receptor antagonist
telmisartan (8) and the anticancer agents paclitaxel and docetaxel (9-10).

Sequence variation in genes encoding OATP family members has been reported to
contribute significantly to interindividual differences in the disposition of many clinically
relevant drugs (11-13). Earlier, our group identified and characterized naturally occurring
polymorphisms in the SLCO1B1 gene associated with significantly impaired transport
activity (14). Among those, the extensively studied common SLCO1B1 variant 521C>T
(Val174Ala) was shown to be associated with increased plasma levels of various statins,
including rosuvastatin, atorvastatin, and pravastatin (15-16). Moreover, in a genome wide
association study, this variant has been recently reported as the most important predictor
of myopathy, a common side effect of statin therapy, which in rare cases can be lifethreatening (17).

The presence of SLCO1B3 coding region variants had been noted earlier using public
databases and genotyping of 182 Caucasian-Europeans, where three non-synonymous
polymorphisms were identified (18). Two common variants, SLCO1B3 334T>G
(Ser112Ala) and 699G>A (Met233Ile), were found to be associated with altered transport
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function in vitro compared with the expressed wild-type protein. Functional implications
and clinical relevance of these two variants have been the subject of several in vivo
studies. Importantly, recent studies suggest SLCO1B3 334T>G and 699G>A influences
the pharmacokinetic profile of a newly identified substrate, mycophenolic acid
glucuronide (MPAG), a metabolite of the immunosuppressant mycophenolic acid (MPA)
(19-20). Renal transplant patients carrying two variant SLCO1B3 334GG alleles
exhibited lower exposure to MPA but higher plasma levels of MPAG in comparison to
334TG and TT carriers, resulting in a significantly reduced metabolic ratio for
MPA/MPAG among the GG carriers.

In the this study, we report the identification and functional assessment of novel,
ethnicity-dependent non-synonymous variants in the SLCO1B3 gene associated with
impaired transport activity for the OATP1B3-specific substrate cholecystokinin (CCK8)
as well as the drug substrate rosuvastatin related to altered expression. We also mapped
the transport-deficient variants onto a recently predicted structural model of OATP1B3 to
further illustrate potential structure-function relationships.

3.2

3.2.1

Materials and methods

Materials

Radiolabeled [3H]-CCK8 (97.0 Ci/mmol, > 96.9% purity) was purchased from
Amersham GE Healthcare UK Limited (Buckinghamshire, England), [3H]-atorvastatin
calcium (10.5 Ci/mmol, > 99% purity) from American Radiolabeled Chemicals, Inc.
(Saint Luis, US), and unlabeled atorvastatin from Toronto Research Chemicals (Toronto,
Canada). [3H]-rosuvastatin (79 Ci/mmol, 97.1% radiochemical purity) and unlabeled
rosuvastatin were provided by Dr. Yi Wang (AstraZeneca, Wilmington, DE). Additional
[3H]-rosuvastatin (5 Ci/mmol, 99% radiochemical purity) was sourced from American
Radiolabeled Chemicals (St. Louis, MO). The pEF6/V5-His-TOPO expression vector
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was purchased from Invitrogen. Genomic DNA isolated from peripheral blood
lymphocytes of healthy volunteers was purchased from Coriell Cell Repositories
(Camden, NJ). All other chemicals and reagents, unless stated otherwise, were obtained
from Sigma-Aldrich Research (St. Louis, MO) and were of the highest grade available.

3.2.2

Identification of SLCO1B3 polymorphisms and determination
of allelic frequencies

Variations in the SLCO1B3 gene were assessed in ethnically defined genomic DNA
samples from healthy subjects (Caucasian-American, African-American, ChineseAmerican and Hispanic-American descent). After amplification of the 14 exons using
polymerase chain reaction (PCR), single nucleotide polymorphisms were determined by
either direct sequencing [n = 92 for each ethnicity, exons 8-11; ABI 3700 DNA Analyzer
(Applied Biosystems Inc., Foster City, California, USA)] or temperature-dependent
capillary electrophoresis [n = 46 for each ethnicity, exons 1 - 7 and 12 – 14, Reveal,
SpectruMedix (State College, Pennsylvania, USA)] of PCR products with subsequent
sequencing of the identified variant samples. Primer sequences are summarized in Table
3.1.

3.2.3

Variant SLCO1B3 plasmid construction

SLCO1B3 variant expression plasmids were created using site-directed mutagenesis as
described earlier (14). Reference sequence (also referred to as SLCO1B3 wildtype;
NM_019844) and presence of polymorphisms was verified by sequencing.

3.2.4

Transient transfection and uptake transport assays

Transient transfection assays were performed using the recombinant vaccinia virus (vTF7) expression method detailed earlier (21). In brief, human cervical carcinoma cells
(HeLa) (American Type Culture Collection, Manassas, Virginia, USA) were seeded into
12-well plates, infected with vaccinia virus, and then transfected with expression plasmid
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or vector control lacking any insert using Lipofectin reagent (Invitrogen). Sixteen hours
thereafter, cells were washed with transport media (Opti-MEM, Invitrogen) and treated
with radiolabeled drug. At various time intervals, cells were washed three times with icecold Dulbecco’s phosphate buffered saline buffer and then lysed with 1% sodium dodecyl
sulfate. Retained cellular radioactivity was quantified by liquid scintillation spectrometry.
Transport experiments evaluating pH sensitivity were carried out as described using
Krebs-Henseleit buffer (118 mM NaCl, 23.8 mM NaHCO3, 4.8 mM KCl, 0.96 mM
KH2PO4, 1.2 mM MgSO4, 12.5 mM HEPES, 5.0 mM glucose, and 1.5 mM CaCl2)
adjusted to pH 6.5, 7.4, or 8 instead of Opti-MEM. Parameters for saturation kinetics
(Vmax and Km) were estimated by nonlinear curve fitting using Prism (GraphPad Software,
Inc., San Diego, California, USA). All experiments were carried out in duplicate on 2 - 3
separate days. Uptake experiments using CCK8 were based on the assumption that there
is no CCK8 metabolism during the initial uptake time period.

3.2.5

OATP1B3 cell surface and total protein expression and
structural mapping

Expression analysis of OATP1B3 at the cell surface and in total cell lysates was carried
out as described earlier (14, 22). Total cell lysates and biotinylated fractions were
subjected to Western blot analysis for detection of OATP1B3 with a rabbit polyclonal
antibody (1:4000) (4), and for the intracellular protein calnexin (1:4000; StressGen,
Victoria, British Columbia, Canada) (14). Bands were visualized using enhanced
chemiluminescence (ECL plus, Amersham, Piscataway, New Jersey, USA). Mapping of
the OATP1B3 variants, His520Pro and Val560Ala, on a recently predicted structural
model of OATP1B3 was carried out as described earlier using PyMOL (www.pymol.org)
(23).
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3.2.6

Statistical analysis

Determination of statistical differences between various group parameters was
determined using either Student's t-test, Mann Whitney U-test or analysis of variance, as
appropriate. A P-value of less than 0.05 was considered to reflect statistical significance.

3.3

3.3.1

Results

Polymorphisms in SLCO1B3 and allelic frequency

Using genomic DNA from diverse ethnic populations, we identified 14 coding region
variants within SLCO1B3 (Table 3.2). Among six non-synonymous polymorphisms
identified, SLCO1B3 439A>G, 767G>C, 1559A>C and 1679T>C were new and
unreported earlier (24). Their location is depicted on a putative OATP1B3 secondary
structure (Figure 3.1). The rare 1564G>T (Gly522Cys)(18), described earlier, was not
detected in our population. The prevalence of SLCO1B3 334T>G, 699G>A, 767G>C,
and 1679T>C was ethnicity-dependent (Tables 3.3 and 3.4). Complete linkage of
334T>G and 699G>A as described earlier by some investigators was not observed in our
study (10, 25-26). SLCO1B3 439A>G and 1559A>C were rare in our study population.

3.3.2

OATP1B3 is the main CCK8 uptake transporter in liver

The peptide hormone CCK8 has been shown to be substrate of OATP1B3 (27), but not of
OATP1B1 (28). To evaluate CCK8 transport activities among other members of the
solute carrier (SLC) superfamily, we transiently expressed an array of human and rat
OATPs, organic cation transporters (OCTs), organic anion transporters (OATs), as well
as the hepatic bile acid transporter sodium taurocholate cotransporting polypeptide
(NTCP). The capacity for CCK8 uptake by OATP1B3 exhibited nearly 150-fold greater
transport activity (Figure 3.2A) compared to cells transfected with the plasmid lacking
OATP1B3 (vector control). The closely related OATP1B1 showed minimal, although
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statistically significant transport of CCK8, but approximately 100-fold less than that
mediated by OATP1B3. Other OATPs, OCT and OAT transporters failed to exhibit any
uptake activity for CCK8. The initial rate of CCK8 uptake by OATP1B3 was
demonstrated to be linear over the first 5 min (Figure 3.2B).

3.3.3

Functional analysis of OATP1B3 variants

An array of expression plasmids comprising SLCO1B3 wild type, six non-synonymous
variants, and the haplotype combination of 334T>G and 699G>A were created. CCK8
transport activities were significantly lower for Met233Ile, His520Pro, and Val560Ala (P
< 0.05) variants relative to wild type (Figure 3.2C). His520Pro and Val560Ala exhibited
approximately 20%, and Met233Ile exhibited approximately 65% CCK8 uptake relative
to wild type. Expression of the Ser112Ala_Met233Ile haplotype showed a slightly more
pronounced decrease to 57% (p < 0.05) than Met233Ile alone.

The transport kinetics of CCK8 was examined for those allelic variants that exhibited a
significant decrease in transport activity (Figure 3.3). The maximum uptake rate (Vmax ±
SD, pmol.mg protein-1.min-1) of CCK8 was decreased for His520Pro, Val560Ala, and
Met233Ile compared to wildtype, whereas Ser112Ala did not differ. The concentration at
which half the maximal uptake occurs (Km ± SD, μM) was slightly altered with an about
two-fold increase for Met233Ile and Val560Ala. Expression of Ser112Ala_Met233Ile
haplotype resulted in values similar to those observed for Met233Ile when expressed
alone.

We also show that rosuvastatin and atorvastatin are substrates of OATP1B3 (Figure
3.4A). Rosuvastatin transport activity was significantly lower for Met233Ile, His520Pro,
and Val560Ala (p < 0.01) variants relative to wildtype, exhibiting 56%, 45% and 54%
uptake, respectively, whereas the linked Ser112Ala_Met233Ile haplotype yielded activity
that is 87% of wildtype (Fig. 4B). Interestingly, no significant differences were observed
for atorvastatin (Figure 3.4C).
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3.3.4

Total and cell surface expression of OATP1B3 variants

Immunoblot analysis (Figure 3.5) suggested a reduction in total OATP1B3 protein
expression for Gly256Ala, His520Pro and Val560Ala, whereas Met233Ile was not
different from wildtype. Interestingly, Ser112Ala and Thr147Ala bands appear slightly
stronger than that of wild type. Cell-surface biotinylation with the membrane-impermeant
biotinylation reagent, sulfosuccinimidyl-2-[biotinamido]ethyl-1,3-dithiopropionate, was
performed to quantify the cell surface expression of each variant. Only His520Pro and
Val560Ala showed lower cell surface expression levels compared to wild type. Cell
surface-expressed OATP1B3 proteins from transfected HeLa cells were highly
glycosylated proteins with an apparent molecular mass of approximately 100 kDa, which
is similar to that observed in human liver and total protein lysates. An additional major
band of approximately 70 - 75 kDa was detected in cell lysates in comparison to human
liver, consistent with the calculated molecular mass of OATP1B3. The two forms of
OATP1B3 in HeLa cells may suggest that a significant fraction of the transfected
OATP1B3 is not glycosylated. The enrichment of cell surface proteins within the
biotinylated fractions was evidenced by the lack of the intracellular protein, calnexin.

3.3.5

Amino acid conservation and structural model

The two functionally most relevant variants, His520Pro and Val560Ala, were mapped
onto a recently proposed structural model of OATP1B3 (Figure 3.6A, B) (23).
Accordingly, the amino acid residue His520 (Figure 3.6A) is located on the large
extracellular loop (ECL) 5 between the transmembrane (TM) regions 9 and 10, and
Val560 (Figure 3.6A, B) in the C-terminal region of TM10, thereby facing the putative
central pore of the transport protein that is speculated to be crucial to substrate
translocation.

The amino acid alignment of OATP1B3 within various orthologs representing the
conserved residues corresponding to the identified nonsynonymous variants is shown in
Figure 3.6C. Only Gly256 appears to be conserved among the five assessed species,
whereas substantial variability is observed for the other amino acid residues.
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3.3.6

Effect of extracellular pH on CCK8 transport by OATP1B3
His520Pro variant

A conserved histidine residue located on the extracellular portion of TM3 was recently
shown to mediate the pH-sensitive OATP1B3 transport activity (29). On the basis of the
predicted extracellular location of the His520Pro variant (ECL5), we evaluated the effect
of extracellular pH on His520-mediated CCK8-transport compared to Pro520 (Figure
3.7). Interestingly, CCK8 transport showed pH dependence for His520 and Pro520 with
maximum stimulation at pH 6.5 with a substantial 3.4-fold, 4-fold and 5-fold decrease in
CCK8 uptake by the variant Pro520 compared with His520 at pH 6.5, 7.4, and 8,
respectively (Figure 3.7A). CCK8 uptake was significantly reduced at pH 8 to 67.7% for
His520, and to 46% for Pro520 of the transport at pH 6.5 (Figure 3.7B). Interestingly, in
comparison with His520, the magnitude of the reduction of transporter function was
greater for the Pro520 variant when the extracellular pH was increased from 6.5 to 7.4 or
8.
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Table 3.1 Oligonucleotide primer sequences to carry out PCR of the SLCO1B3
coding region
Exon

Forward primer

Reverse primer

1

5’-catttcaaaccaagcatcagc-3’

5’-taataaatggctcagagctg-3’

2

5’-cgagtaaagaagaaaaactg-3’

5’-acttatgcaagtatggttatca-3’

3

5’-gggcattcagttctactaga-3’

5’-taataaatggctcagagctg-3’

4

5’-atttctctgtatttctggga-3’

5’-tcagaaactttatagacgtg-3’

5

5’-taaaacactctcttgtctcg-3’

5’-gtagatccagggaatgtaat-3’

6

5’-ccaagtatttgtgacatctga-3’

5’-aatggtgtcctgcacttaaaa-3’

7

5’-aacgatttttgactggcttctt-3’

5’-aatcctcttcccctttttatgta-3’

8

5’-gcctcacaaatcatttgtaac-3’

5’-gcagtgtttcatttatcaagc-3’

9

5’-gacatatcagaaaaaccata-3’

5’-gatggttaacatattacaca-3’

10

5’-tcttctgctctttctctact-3’

5’-taaggagaggagaaaaagtg-3’

11

5’-ggcaaatgtatttgttaatatttcaa-3’

5’-tgttttacaggatcatactta-3’

12

5’-gaatgatgctgataaatgtt-3’

5’-tgcattcagtctttagtatt-3’

13

5’-cgctcagttacatttgaagc-3’

5’-gaaatgtgtttacgacaact-3’

14

5’-ctggggagaaaaaaatgtaag-3’

5’-caggaacacctcaaaaataac-3’
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Table 3.2 SLCO1B3 gene coding region variants
Nucleotide

Reference

Variant

change

AA change

Exon

sequence

sequence

rs number

69C>T

Arg23Arg

1

GACGCTGCA

GACGTTGCA

334T>G

Ser112Ala

3

GACATCTTT

GACAGCTTT

rs4149117

439A>G

Thr147Ala

4

TCAAACCTT

TCAAGCCTT

rs57585902

699G>A

Met233Ile

6

AAATGTACG

AAATATACG

rs7311358

759T>A

Arg253Arg

7

CTCGTTGGG

CTCGATGGG

rs61736830

767G>C

Gly256Ala

7

GTTGGAGCT

GTTGCAGCT

rs60140950

924A>T

Thr308Thr

7

AAACAGCTA

AAACTGCTA

1557A>G

Ala519Ala

11

CAGCACACT

CAGCGCACT

1559A>C

His520Pro

11

GCACACTTG

GCACCCTTG

1593A>G

Thr531Thr

11

GTACAAGGA

GTACGAGGA

1614T>C

Val538Val

11

ATGTTGCAA

ATGTCGCAA

rs77851390

1679T>C

Val560Ala

11

ACTGTGAAg

ACTGCGAAg

rs12299012

1833G>A

Gly611Gly

13

AAGGGGCTT

AAGGAGCTT

rs3764006

1997G>A

Ser659Ser

14

CATCGGACA

CATCAGACA

rs60571683

rs2053098
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Table 3.3 Allelic and genotype frequencies of non-synonymous SLCO1B3 gene
variants among different ethnic populations

SLCO1B3

African

Caucasian-

Chinese-

Hispanic-

Americans

Americans

Americans

Americans

All

N

%

N

%

N

%

N

%

N

%

T/T

19

43.2

17

38.6

12

26.1

8

17.8

56

31.3

T/G

16

36.4

8

18.2

11

23.9

10

22.2

45

25.1

G/G

9

20.5

19

43.2

23

50

27

60

78

43.6

Total

44

100

44

100

46

100

45

100

179

100

q

0.386

334T>G

0.523

0.620

0.711

0.561

439A>G
A/A

45

97.8

45

100

46

100

44

100

180

99.4

A/G

1

2.2

0

0

0

0

0

0

1

0.6

G/G

0

0

0

0

0

0

0

0

0

0

Total

46

100

45

100

46

100

44

100

181

100

q

0.011

0

0

0

0.003

699G>A
G/G

10

21.7

6

14.0

1

2.3

2

4.4

19

10.7

G/A

28

60.9

7

16.3

16

36.4

11

24.4

62

34.8

A/A

8

17.4

30

69.8

27

61.4

32

71.1

97

54.5

Total

46

100

43

100

44

100

45

100

178

100

56

q

0.478

0.779

0.795

0.833

0.719

767G>C
G/G

43

93.5

30

66.7

46

100

40

88.9

159

87.4

G/C

3

6.5

14

31.1

0

0

5

11.1

22

12.1

C/C

0

0

1

2.2

0

0

0

0.0

1

0.5

Total

46

100

45

100

46

100

45

100

182

100

q

0.033

0.178

0

0.056

0.066

1559A>C
A/A

69

100

87

100

81

98.8

76

100

313

99.7

A/C

0

0

0

0

1

1.2

0

0

1

0.3

C/C

0

0

0

0

0

0

0

0

0

0

Total

69

100

87

100

82

100

76

100

314

100

q

0

0

0.006

0

0.002

1679T>C
T/T

64

92.8

87

100

82

100

76

100

309

98.4

T/C

5

7.2

0

0

0

0

0

0

5

1.6

C/C

0

0

0

0

0

0

0

0

0

0

Total

69

100

87

100

82

100

76

100

314

100

q

0.036

0

0

N, number of individuals; q, frequency of variant allele

0

0.008
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Table 3.4 Minor Allelic Frequency (%) of functional SLCO1B3 polymorphisms
Minor Allelic Frequency (%)
rs number

rs4149117

rs7311358

-

rs12299012

SLCO1B3

334T>G

699G>A

1559A>C

1679T>C

Ser112Ala

Met233Ile

His520Pro

Val560Ala

Effect
Reference

Ethnicity

Our study

EuropeanAmerican

52

78

0

0

Our study

AfricanAmerican

39

48

0

3.6

Our study

ChineseAmerican

62

80

0.6

0

Our study
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(Chinese)
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Letschert et
al. (18)

European
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Franke et al.

not specified
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80

0
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(25)
Smith et al.
(10)

EuropeanCaucasian

81

83

nd

nd

Smith et al.
(10)

AmericanCaucasian

88

87

nd

nd

Smith et al.
(10)

AfricanAmerican

41

41

nd

nd

Smith et al.
(10)

Mexican

78

79

nd

nd

Smith et al.
(10)

Han Chinese

80

77

nd

nd

Smith et al.
(10)

Ghanaian

38

38

nd

nd

Baker et al.
(32)

not specified

85

84

0

1.6

Tsujimoto et
al. (26)

Japanese

73

73

nd

nd

Results from this study were compared with previous entries in pharmacogenomic databases and
publications among different ethnicities. Perlegen (AFD) and HapMap data were accessed on March 3rd
2009 via http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=snp; nd, not determined
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Ser112Ala
Met233Ile

Gly256Ala

Thr147Ala

His520Pro

Val560Ala

Figure 3.1 Schematic representation of organic anion-transporting polypeptide 1B3
(OATP1B3)
Transmembrane topology is based on predictions using TopPred2
(http://bioweb.pasteur.fr/seqanal/interfaces/toppred.html) and is in agreement with the
recently published OATP1B3 model (23). Non-synonymous nucleotide substitutions are
indicated by arrows. The transmembrane topology schematic was rendered using TOPO2
(S.J. Johns and R.C. Speth, transmembrane protein display software,
http://www.sacs.ucsf.edu/TOPO2/, unpublished)
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Figure 3.2

[3H]-CCK8 uptake transport activity (0.1 µM) following transient

heterologous expression in HeLa cells. (A) Uptake of [3H]-CCK8 by cells transfected with
various human organic anion-transporting polypeptides (OATPs) including OATP1B3,
OATP2B1, OATP1B1, and OATP1A2, and the uptake transporters sodium taurocholate
cotransporting polypeptide (NTCP), organic cation transporter 1 (OCT1), and organic anion
transporter (OAT) 1 and 3 as well as several rat orthologs. Values are expressed as percent of
cellular uptake by vector control. (B) Time course of [3H]-CCK8 uptake [pmol/mg protein]
in OATP1B3 over-expressing cells compared to transporter-lacking vector control (VC). (C)
Uptake of [3H]-CCK8 by cells transfected with SLCO1B3 variants relative to wild type at 10
minutes. Values are expressed as percent of cellular uptake by OATP1B3 wild type. All
values are given as mean ± S.E. or mean ± SD (Fig 2B only) of at least two to three
independent experiments with a total of n = 5 - 6. *p<0.05, **p < 0.01
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Figure 3.2 [3H]-CCK8 uptake transport activity (0.1 µM) following transient
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Figure 3.3

Transport kinetics of organic anion-transporting polypeptide 1B3

(OATP1B3) following transient heterologous expression in HeLa cells conducted at 5
min at varying concentrations of CCK8 (1-50 µM). Parameters for saturation kinetics
(Vmax and Km) were estimated by nonlinear curve fitting using Prism (GraphPad Software,
Inc., San Diego, CA). Data are expressed as mean ± S.E. (n = 4 - 6).
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Figure 3.3 Transport kinetics of organic anion-transporting polypeptide 1B3
(OATP1B3) following transient heterologous expression in HeLa cells conducted at
5 min at varying concentrations of CCK8 (1-50 µM).
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Figure 3.4 Rosuvastatin and atorvastatin uptake transport activity (0.1µM) following
transient heterologous expression of organic anion-transporting polypeptide 1B3
(OATP1B3) in HeLa cells. (A) Uptake of [3H]-rosuvastatin and [3H]-atorvastatin by
OATP1B3 over-expressing cells at 5 minutes compared to transporter lacking vector control
[pmol/mg protein]. (B) Uptake of [3H]-rosuvastatin and (C) [3H]-atorvastatin by cells
transfected with SLCO1B3 variants relative to wildtype at 5 min. Values are expressed as
percent of cellular uptake by OATP1B3 wildtype and given as mean ± S.E. of three
independent experiments with a total n ≥ 5 (two for atorvastatin with n = 4). **p < 0.001
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Figure 3.5 Total (left panel) and cell surface protein expression (right panel) of
organic anion-transporting polypeptide 1B3 (OATP1B3) variants in comparison to
wild type and vector control lacking any insert.
Total cell lysate containing biotinylated and non-biotinylated proteins, and cell surfaceexpressed biotinylated proteins (captured on streptavidin beads) were subjected to SDSPAGE, and transferred onto nitrocellulose membranes. Immunoblots were probed with
anti-OATP1B3 antibody (top panels) and then stripped and probed with anti-calnexin
antibody (bottom panels). For comparison, immunoblot of human liver protein lysate
(most left panel) probed with anti-OATP1B3 antibody. HeLa cells, human cervical
carcinoma cells
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Figure 3.6 Organic anion transporting polypeptide 1B3 (OATP1B3) variants V560A
and H520P mapped on to the earlier described structural model of OATP1B3 (23)
viewed from (A) the lateral side and (B) the intracellular side. Helices are shown as
cylinders and beta sheets as sheets. The model consists of two main regions: the membranespanning helices [also transmembrane domain (TM); green] that form a pore and the
extracellular Kazal-type serine protease inhibitor-like domain (red), which links TM9 and
TM10 (labeled and colored yellow and dark green, respectively). The side chain of V560 at
the C-terminal region of TM10 is shown to point towards the pore. The position of H520 is
mapped roughly on to the un-modeled loop, which connects the Kazal-type domain and the
N-terminus of TM10. The Figure was generated with PyMOL (www.pymol.org). (C) Amino
acid alignment of human OATP1B3 with various orthologs by ClustalW algorithm. Arrows
indicate positions of non-synonymous variants.
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Figure 3.6 Organic anion transporting polypeptide 1B3 (OATP1B3) variants
V560A and H520P mapped on to the earlier described structural model of
OATP1B3 (23) viewed from (A) the lateral side and (B) the intracellular side.
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Figure 3.7 Effect of organic anion-transporting polypeptide 1B3 (OATP1B3) His520 in
comparison to the variant OATP1B3 Pro520 on pH-sensitivity. [3H]-CCK8 uptake in
transiently transfected HeLa cells at 3 nM was measured for 5 min at 37°C at pH 6.5, 7.4,
and 8.0. Results are expressed as mean ± S.E. of duplicate determinations from 3
independently performed transport studies. (A) Absolute CCK8 uptake [fmol/mg protein],
OATP1B3 520His: pH6.5: 64.6 ± 5.5, pH7.4: 53.9 ± 5.6, pH8: 43.7 ± 4.2; and for OATP1B3
520Pro: pH6.5: 18.9 ± 2.1, pH7.4: 13.6 ± 1.1, pH8: 8.7 ± 1.3. (B) [3H]-CCK8 uptake relative
to pH6.5 with uptake values corrected for unspecific transport in HeLa cells and normalized
to uptake at pH 6.5 (= 100%). (C) Reduction of transporter function [%] from pH 6.5 to 7.4
or 8. *p < 0.05
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Figure 3.7 Effect of organic anion-transporting polypeptide 1B3 (OATP1B3)
His520 in comparison to the variant OATP1B3 Pro520 on pH-sensitivity.
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3.4

Discussion

OATP transporters, particularly those in the OATP1B subfamily, are important for the
liver-specific drug uptake. For OATP1B1, commonly occurring functional variants, first
reported by our group (14), have now been shown to be a key predictor of altered
substrate drug levels and responses (15-17). In vitro evidence further suggests that
OATP1B3 is involved in the hepatic uptake of clinically relevant drugs such as the
anticancer agents, methotrexate, docetaxel and paclitaxel (3, 9), and the angiotensin II
receptor antagonists, olmesartan and telmisartan (6, 8). We had shown earlier that in
human liver, expression of OATP1B1 and OATP1B3 are similar, at least when mRNA
levels were quantified (4). Given that many drug substrates of OATP1B1 are also shared
substrates of OATP1B3, genetic variation in SLCO1B3 is likely one of the determinants
of their variable disposition in vivo. Presence of genetic variation in SLCO1B3 has been
reported and, in some cases, clinical relevance has also been noted (19-20).

In this study, we carried out a comprehensive analysis for OATP1B3 function in terms of
genetic variation and substrate specificity. First, we performed a large genotypic analysis
to identify SLCO1B3 variants in ethnically diverse individuals. Within the SLCO1B3
coding region, we identified a total of six non-synonymous polymorphisms, including
four novel variants. We further detected the previously described common variants
334T>G and 699G>A (18) that were not observed to be in complete linkage. This was
also noted by some (18) but not all (10, 25-26) investigators. Overall our results indicate
that the coding region of SLCO1B3 is less polymorphic in comparison with SLCO1B1,
encoding the closely related OATP1B1 protein of the same subfamily (14). Interestingly,
the novel impaired-function polymorphism 1679T>C (Val560Ala) was only observed in
African-Americans with an allelic frequency of 3.6%. In contrast SLCO1B3 334T>G and
699G>A were less frequent in African-Americans compared with other ethnicities (Table
3.4).
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Two novel variants, OATP1B3 His520Pro and Val560Ala, exhibited markedly lower
uptake activity for CCK8 and rosuvastatin compared with wild type when studied in
HeLa cells. Among earlier reported variants, only Met233Ile but not Ser112Ala showed
decreased uptake of CCK8 and rosuvastatin, and the Ser112Ala_Met233Ile haplotype did
not exhibit any additional reduction in transport activity. Earlier studies have reported
conflicting results regarding the effect of these two variants, either alone or co-expressed.
Letschert et al. (18) observed increased CCK8 transport in Madin-Darby canine kidney
strain II (MDCKII) cells stably expressing Ser112Ala and Met233Ile whereas their
expression in human embryonic kidney 239 (HEK239) cells did not result in a difference
compared with wild type. In contrast, expression of the Ser112Ala_Met233Ile haplotype
showed decreased uptake activity for two recently reported OATP1B3 substrates,
testosterone and MPAG (20, 30), after expression in Cos-7 and HEK cells, respectively,
but no difference was found for the chemotherapeutic drug substrate, paclitaxel, when
assessed in Xenopus laevis oocytes (9-10). The divergent findings may suggest substratespecific effects but also be in part explained by the use of different cell systems with
varying levels of uncharacterized endogenous transporters with overlapping substrate
specificity.

Kinetic analysis of OATP1B3-mediated CCK8 transport in HeLa cells revealed that
Met233Ile, His520Pro and Val560Ala as well as the Ser112Ala_Met233Ile combination
result in reduced Vmax without altering the apparent affinity (Km). The Km value of 4.2
mol/L for the wild type protein observed in this study was in close agreement with
CCK8 uptake results measured in X. leavis oocytes expressing human OATP1B3 (Km
11.1 mol/L) as well as in primary cultured rat hepatocytes (Km 6.7 mol/L) (27).

In addition to altered substrate recognition, changes in expression of functional proteins
or failure of the variant protein to reach the cell surface are known to influence the
magnitude of overall transport function. In our study, the total expressed level of the two
variant proteins His520Pro and Val560Ala was found to be reduced compared with the
wild type. Furthermore, these two variant proteins revealed a reduced cell surface
expression. This is consistent with findings reported earlier (20). Two other OATP1B3
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variants, namely Gly522Cys and Gly583Glu, showed decreased intrinsic clearance using
bromosulfophthalein as a result of impaired Vmax values but comparable Km (18), and
variant proteins were shown to be mainly retained intracellularly in comparison with wild
type. Similarly, the OATP1B1 Val174Ala (*5) variant was found to decrease Vmax with
no significant effect on Km using various substrates, and cell surface trafficking was
shown to be the major determinant for its functional effect in vitro (14). Subsequently,
numerous clinical studies were able to demonstrate the functional relevance of
OATP1B1*5 in vivo (15-16). In summary, our results suggest that the observed
alterations in transport activity, in part, may result from decreased total protein and, in
some cases, cell surface targeting of the variant OATP1B3. Decreased total protein
expression was also observed for Gly256Ala, however there was no significant
impairment of CCK8 transport activity.

The substitution of the histidine residue in position 520 by proline, causing impaired
function of OATP1B3, is predicted to localize to the putative large extracellular loop
(ECL) 5 between transmembrane helix (TM) 9 and TM10. The large ECL5 – common to
all OATPs – has been proposed to play an important role in the substrate-transporter
interaction and surface expression (14, 23, 31). Ten conserved cysteine residues within
this loop were shown to affect transport function and cell surface trafficking in
OATP2B1, another OATP family member (31). Interestingly, naturally occurring
polymorphisms resulting in amino acid substitutions within ECL5 of OATP1B3
(His520Pro, Gly522Cys, Gly583Glu) (18, 24) and OATP1B1 (Gly488Ala) (14) do not
directly involve any cysteine residues but were observed to be functionally impaired,
partially due to decreased total protein expression and/or reduced cell surface trafficking.
This suggests that non-cysteine amino acid variations present in the large ECL may be
indirectly associated with the disulfide bond formation among cysteine residues. The
possibility of altered substrate interaction with the transporter is also substantiated by the
fact that the variant amino acid substitutions alter transport activity only for some but not
all OATP1B3 substrates, as observed in this study for OATP1B3 His520Pro and reported
for the OATP1B3 Gly522Cys variants (18).
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The loss-of-function Val560Ala substitution is localized to TM10 of OATP1B3. A recent
report using a TM domain swapping strategy indicated that TM10 is important for CCK8
transport by OATP1B3 (28). Replacing TM10 of OATP1B3 with TM10 of OATP1B1
nearly abolished its ability to transport the OATP1B3-specific substrate, CCK8. Three
key amino acids within this region, Tyr537, Ser545, and Thr550, were shown to cause the
observed effect. Interestingly, replacement of Thr559 in OATP1B3 to the respective
residue in OATP1B1 (Ile559) also caused a significant decrease in CCK8 uptake (70% of
OATP1B3), thus the profound loss-of-function noted in this study for the variant that
results in the exchange of Val560 to Ala560 is consistent with this region being critical
for substrate specificity. Notably when mapped onto a recently suggested model of
OATP1B3 (23), the side chain of the Val560 residue at the C-terminal region of TM10
faces the putative central pore (Figure 3.6). Thus, our findings provide new and important
evidence that the central pore, particularly the C-terminal region of TM10, is most likely
of functional relevance for OATP1B3.

Recent studies also suggest that transport activity for OATPs is modulated by pH, and
that higher transport activity is observed at a lower (acidic) extracellular pH, resulting in
increased substrate affinity as evidenced by lower Km values (29). The His130 residue
(TM3) likely facing the extracellular milieu had been identified to be crucial for the
observed pH sensitivity in OATPs including OATP1B3. The replacement of the basic
histidine residue with a neutral glutamine abolished pH dependence of transport of a rat
Oatp family member, Oatp1a1, and exchange of glutamine with histidine in OATP1C1
created pH dependence of a formerly pH independent transporter. Our study identified a
non-synonymous variant that results in a histidine residue in ECL5 of OATP1B3 that is
replaced by the less polar and weekly basic proline. Comparing CCK8 transport activity
of the wild type protein containing His520 with the variant Pro520 at extracellular pH of
6.5, 7.4, and 8.5 revealed pH dependence for His520 and the Pro520 variant with
maximum activation of uptake under acidic conditions (pH 6.5 > pH 7.4 > pH 8),
although the magnitude in reduction of transporter function seemed to be greater for the
Pro520 variant when the extracellular pH was increased from 6.5 to 7.4 or 8.
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Recently, the clinical relevance of SLCO1B3 polymorphisms has been evaluated for
various drug substrates of OATP1B3. Drug exposure of two widely used
chemotherapeutics, paclitaxel and docetaxel, was assessed with respect to SLCO1B3 gene
variants in cancer patients (10, 32). No association was observed between SLCO1B3
variants with pharmacokinetics of docetaxel and paclitaxel. This negative finding may be
explained, in part, by the small patient numbers (<100) in case of the more rare variants,
1559A>C and 1679T>C, and the potential involvement of other transporter proteins.
More recently, SLCO1B3 334T>G and 699G>A were reported to determine the
pharmacokinetics of the immunosuppressant mycophenolic acid in renal transplant
patients, with higher mycophenolic acid glucuronide exposure in variant carriers
compared to wild type suggesting lower systemic clearance due to decreased hepatic
uptake (20, 33).

In conclusion, we have identified and functionally characterized novel non-synonymous
polymorphisms in the SLCO1B3 gene associated with impaired transport in vitro.
Notably, SLCO1B3 1679T>C (Val560Ala) with an allelic frequency of 3.6% in AfricanAmericans is a, heretofore, unrecognized loss-of-function polymorphism with the
potential to affect substrate drug disposition in vivo. Importantly, detailed kinetic
analysis, total and cell surface expression data, variant-associated pH dependence, and
computational mapping of OATP1B3 variants further outline the complexity and
potential functional relevance of these polymorphisms.
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4

2

THE BILE ACID TRANSPORTER ORGANIC SOLUTE
TRANSPORTER (OST) ALPHA-BETA IS ALSO AN
INTESTINAL DRUG TRANSPORTER2

The material in this chapter is based on a manuscript in preparation: Schwarz UI, Meyer
zu Schwabedissen HE, Yip C, Leon-Ponte M, Leake B, Ho RH, Urquhart BL, Tirona
RG, Haywood J, Dawson PA, and Kim RB. The bile acid transporter organic solute
transporter (OST) αβ is also an intestinal drug transporter. 2012

82

4.1

Introduction

Contribution of the organic solute transporter (OST) αβ for recirculation of bile acids is
well established. Most of bile acids (>90%) are reabsorbed from the small intestine and
returned to the liver, thus preserving bile acid homeostasis (1-2). This efficient and high
capacity process involves a series of membrane carriers (3). In the liver, newly
synthesized and recycled bile acids are (re)secreted into bile via the canalicular bile salt
export pump (BSEP; ABCB11). The bile acids pass into the small intestine where they are
actively absorbed from the intestinal lumen by the apical sodium-dependent bile acid
transporter (ASBT; SLC10A2). The bile acids are then efficiently exported across the
basolateral membrane into the portal circulation by the heteromeric transporter, OSTαβ
(OST, SLC51A1; OST, SLC51A1BP). At the sinusoidal membrane of hepatocytes, bile
acids are then taken up into the liver by the Na+ taurocholate cotransporting polypeptide
(NTCP; SLC10A1) and by members of the organic anion transporting polypeptide
(OATP) family. In addition to the ileum, OSTαβ is also expressed on the basolateral
membranes of cholangiocytes to enable the cholehepatic shunting, and at the basolateral
pole of renal proximal tubular cells providing reabsorptive capacity. The findings to date
indicate that OSTαβ plays a critical role in the enterohepatic bile acid circulation to
minimize fecal and urinary bile acid loss and to restrict these potentially cytotoxic
detergents to the intestinal and hepatobiliary compartments.
OST transport activity requires the expression of both subunits, OSTα and OSTβ (4-5). It
is likely that OSTα and OSTβ are dedicated partners. Indeed, expression of individual
subunits in vitro leads to rapid degradation of both proteins, and Ostα-/- knockout mice
lack both Ostα and Ostβ protein despite persistent OSTβ mRNA expression (6-7).
Although encoded on two different chromosomes, their intestinal expression appears to
be coordinately regulated, and expression of both genes is induced by bile acids acting
via the Farnesoid X receptor (FXR). This nuclear receptor controls bile acid homeostasis
by regulating genes in the intestine, liver and kidney important for bile acid synthesis and
transport (8-11). For example, after binding bile acids and translocation into the nucleus,
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the FXR complex directly interacts with FXR elements in the promoters of OSTα and
OSTβ, inducing gene and protein expression allowing potentially harmful bile acids to be
efficiently removed from the enterocyte and exported into the portal circulation.

In addition to a major role in the enterohepatic circulation of bile acids, several lines of
evidence suggest that OSTαβ has other important physiological functions. OSTαβ mRNA
expression is detected in a wide range of human tissues including adrenal gland and
brain. As shown in Xenopus leavis oocytes, OSTαβ operates by facilitated diffusion and
is capable of mediating uptake and efflux of solutes, depending on the substrate's
electrochemical gradient (12). OSTαβ substrates are bile acids including the taurine and
glycine conjugates of cholic acid, deoxycholic acid, chenodeoxycholic acid, and
ursodeoxycholic acid (4-5). However, unlike the ASBT, which functions as a dedicated
bile acid transporter, a preliminary characterization has revealed that OSTαβ transports
other organic solutes in addition to bile acids, including steroids (estrone-3-sulfate,
dehydroepiandrosterone-3-sulfate) and eicosanoids (prostaglandin E2). Xenobiotic
substrates, however, are largely unexplored, and the cardiac glycoside digoxin remains
the only reported drug substrate of OSTαβ to date (4-5).

In the present study we show a number of structurally divergent drugs are substrates of
OSTαβ. In addition, we are able to more fully characterize organ-specific as well as
regional differences in intestinal expression of this transporter from human intestinal
biopsy samples. We propose OSTαβ as an important basolateral bile acid and drug
transporter with an unexpectedly broad substrate specificity that may be more important
to intestinal drug absorption than currently recognized.
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4.2

4.2.1

Methods

Materials

[3H]atorvastatin calcium (10.5 Ci/mmol, >99% purity), [3H]ezetimibe (45Ci/mmol, >99%
purity), [3H]rosuvastatin calcium (5 Ci/mmol, >99% purity), [3H]docetaxel (30 Ci/mmol,
>99% purity), and [3H]paclitaxel (20 Ci/mmol, >99% purity) were purchased from
American Radiolabeled Chemicals, Inc. (Saint Luis, MO), and [3H]taurocholate (5
Ci/mmol, >97% purity from PerkinElmer (Waltham, MA). [3H]sulfasalazine (115.33
µCi/mg, >99% purity) was kindly provided by Pfizer Global Research and Development
(Ann Arbor, Michigan). Paclitaxel, docetaxel, atorvastatin, rosuvastatin, etoposide,
doxorubicin, ezetimibe, and ezetimibe glucuronide were obtained from Toronto Research
Chemicals

(Toronto,

Canada),

and

sulfasalazine,

taurocholate,

methotrexate,

cyclosporine, mitoxantrone, gemfibrozil, ibuprofen, indomethacin, and probenecid from
Sigma-Aldrich (St. Louis, MO). All other chemicals and reagents, unless stated
otherwise, were of the highest grade and readily available from commercial sources.

4.2.2

Wild-type and variant human OSTα and OSTβ plasmid
construction

OSTα and OSTβ cDNAs for the open reading frames (ORFs) were Taq polymerase
amplified from human liver cDNA using 5’-GATTGCTGGAGAGAACGCGGCGAT-3’
(forward primer) and 5’-TTGTCCAAGCCATCCACCTTAGG-3’ (reverse primer) for
OSTα,

and

5’-CTCGTTGCACACGCTACCAGGAGC-3’

and

5’-

GCTTAGGATGGGGCTTCTCTGAAC-3’ for OSTβ, and cloned into the expression
vector pEF6/V5-His TOPO® (Invitrogen). Concordance with the reported reference
sequence (OSTα, NM152672, version 5 [also AY194243]; OSTβ, NM178859, version 2
[also AY194242]) was confirmed by sequencing. A pEF6/V5-His TOPO plasmid
containing the ORF from NTCP from our laboratory was utilized for efflux studies (13).
A

review

of

public

SNP

databases

(dbSNP

database,

NCBI,
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http://www.ncbi.nlm.nih.gov/SNP/,

accessed

August

2010)

revealed

two

non-

synonymous single nucleotide polymorphisms (SNPs), OSTα c.604G>A (Val202Ile;
rs939885) and OSTβ c.362C>T (Pro121Leu; rs75962063) validated by frequency.
Corresponding OSTα and OSTβ variant expression plasmids were created using sitedirected mutagenesis according to the manufacturer. Table S1 lists primers used
(Supplemental Information, Appendix A).

4.2.3

Mouse Ostα and Ostβ plasmid construction

mOstα and mOstβ cDNAs for the open reading frames (ORFs) were Taq polymerase
amplified (Expand long template PCR system, Roche Diagnostics, Mannheim, Germany)
from mouse kidney cDNA using 5’-GAGAGAAAAGAAGGATGGAGCCAGGCAG-3’
(forward primer) and 5’-TCCAGGGTCCAAGCCACTCTCCTCAGGC-3’ (reverse
primer) for OSTα, and 5’-CAGGAGCAGAAACATGGACCACAGTGC-3’ and 5’CTAGCTCTCTGTTTCCTGTGGGTCTGG-3’ for OSTβ, and cloned into pEF6/V5-His
TOPO®. Concordance with the reported reference sequence (mOstα, NM145932, version
5; mOstβ, NM178933, version 2) was confirmed by sequencing.

4.2.4

Transport and inhibition studies

The transport study was carried out in HeLa cell monolayers using 3H-labeled drug
substrates as outlined previously (14). The following final drug concentrations were used:
4 µM taurocholic acid (TCA), 1 µM docetaxel, 1 µM paclitaxel, 0.1 µM rosuvastatin, 0.1
µM atorvastatin, 1 µM sulfasalazine, and 1 µM ezetimibe. Transporter-dependent uptake
was determined in parallel experiments as the difference in intracellular drug
accumulation between the parental plasmid DNA- (lacking OST/mOstα or OST/mOstβ
cDNA) and the transporter DNA-transfected HeLa cells. Transporter-dependent efflux
was determined in parallel experiments as the difference in intracellular drug
accumulation between NTCP transfected HeLa cells compared with NTCP – OSTαβ
cotransfected cells. To measure TCA, rosuvastatin, and docetaxel transport kinetics,
radiolabeled drug uptake during the linear phase (the first 1 min or 2.5 min, respectively)
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was assessed in the presence of varying concentrations of unlabeled respective
compounds. Background transport in HeLa cells was determined by carrying out parallel
experiments using the parental plasmid DNA lacking the transporter cDNA insert, and
this value was then subtracted from the total uptake rate seen in the presence of the
transporter cDNA. Parameters for saturation kinetics (Vmax and Km) were estimated by
Michaelis-Menten-type nonlinear curve fitting using Prism (GraphPad Software, Inc.,
San Diego, CA). Transport experiments evaluating inhibition of OSTαβ-mediated uptake
were carried out with the prototypic substrate TCA as described above. Inhibitors (25µM,
in OPTIMEM I medium) were added to cells for 5 min at 37C prior to uptake initiation.
All experiments were carried out in duplicate or triplicate on at least 2 to 3 separate
experimental days.

4.2.5

Human samples from intestine, liver and kidney

Intestinal biopsy samples (duodenum, terminal ileum and colon) were obtained within a
previous study from patients undergoing diagnostic esophagogastro-duodenoscopy or
colonoscopy (15). Human liver samples were described previously (13). Pooled liver
RNA (5 donors), kidney RNA (A507273), and kidney protein lysate (Lot #A702162)
were purchased from BioChain (Hayward, CA).

4.2.6

Real-time PCR

Reverse transcription was carried out as described previously using total RNA (phenol
chloroform extraction method) isolated from jejunum, ileum, or liver (15).
Complementary DNA (cDNA) was synthesized using the High-capacity cDNA Archive
Kit (Applied Biosystems) and random priming after RNA quantification and confirmation
of integrity (Bioanalyzer, Agilent). mRNA expression was measured by SYBR green
real-time polymerase chain reaction (PCR) with the ABI 7500 sequence detection system
(Applied Biosystems). Transcript levels of cDNAs were normalized to either beta-Actin
or the enterocyte-specific marker villin, and relative expression determined using the 2-
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method (16). Table S2 lists the primer sets used (Supplemental Information,

Appendix A).

4.2.7

Western blotting by SDS-PAGE

Samples for protein analysis were homogenized in 1 mM EDTA, 10 mM Tris, pH = 7.4
with protease inhibitor (Complete, Roche Applied Science, Indianapolis, IN), and
sonicated. Liver homogenates were further centrifuged for 15min at 12,500xg (4C),
followed by ultracentrifugation of the supernatant (70min, 105,000xg, 4C), and the
resulting pellet (membrane-enriched fractions) utilized for Western Blotting. Total
protein was quantified using the BCA Protein Assay (Pierce, Rockford, IL). UV
absorbance (543 nm) was determined on a Multiscan Spectrum (Thermo Electron
Corporation). Samples (15 µg of total protein) were diluted with NuPage sample buffer
and reducing agent, heated at 70C for 10 min, and loaded onto 4-12% Bis-Tris gradient
gels (Invitrogen, Carlsbad, CA), separated by SDS-PAGE, and transferred onto
nitrocellulose membranes. Following overnight blocking with 10% milk at 4C, blots
were probed with a polyclonal antibody to the C-terminal peptide of OSTα (1:500
dilution;

YETFSSPDLDLNLKA,

0754A)

or

OSTβ

(1:500

dilution;

NLRETLLSEKPNLAC, D0297) custom-made (Invitrogen, Carlsbad, CA) after
purification from rabbit antiserum using MelonTM Gel IgG Spin Purification Kit (Pierce
Biotechnologies). Due to lack of OSTβ detection with the latter custom-made antibody, a
polyclonal antihuman OSTβ antibody (1:50 dilution, HPA008533, Sigma) and a
polyclonal anti-mouse Ostβ antibody (1:500 dilution) (8) were tested. The anti-mouse
Ostβ antibody resulted in unspecific cross-reactivity with human samples and could not
be applied (data not shown), whereas the use of the commercial OSTβ antibody was
largely limited by a high antibody concentration required, which was only sufficient for
single use. After probing with the appropriate secondary antibody, protein was visualized
by chemiluminescence detection using the ECL Plus system (Amersham, Piscataway, NJ)
and images captured using the Kodak 4000 mm Image Station (Mandel, Guelph, ON).
Blots were stripped (Restore, Pierce, Rockford, IL) and subsequently reprobed with
primary antibodies against villin (mouse monoclonal Ab-1, 1:500 dilution, Thermo
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Scientific, Waltham, MA), calnexin (rabbit polyclonal, 1:1000 dilution, Stressgen, Ann
Arbor, MI), or actin (goat polyclonal, 1:400, Santa Cruz Biotechnology, Santa Cruz, CA)
to normalize sample loading. Densitometric analysis was performed using ImageJ
(http://rsb.info.nih.gov/ij/).

4.2.8

Cell surface expression

Cell surface biotinylation was carried out as previously described to determine the extent
of cell surface trafficking of heterologously expressed transporters (14). Briefly, HeLa
cells were transfected as described for transport studies. For cell surface expression, 140
μl of streptavidin-agarose beads (Thermo Scientific, Rockford, IL) were added to 600 μl
of cell lysate (containing 1 x 106 HeLa transfected cells), and incubated for one hour at
room temperature. Beads were washed four times with ice-cold lysis buffer, and
biotinylated proteins released from the beads by adding Laemmli buffer. Biotinylated
(cell surface expressed) fractions and total cell lysates (14 µg protein, respectively) were
subjected to Western blot analysis for detection of OSTα (1:500 dilution), and OSTβ
(1:200 dilution) by polyclonal antibodies as described above. The intracellular protein
calnexin was probed as a loading control for total protein, and negative control for cell
surface protein (1:1000 dilution, Abcam, Cambridge, MA), and the cell membrane
protein Na-K ATPase was used as a loading control for cell surface protein (1:250,
Axxora LLC, San Diego, CA).

4.2.9

Animal experiments

Ostα-/- and age-matched wild-type female mice (C57Bl/6 background) were used for the
in situ transport studies. Mice were fasted for 4 hours, anesthetized using inhaled 4%
isoflurane/2% oxygen, and maintained under anesthesia using 2-3% isoflurane/2%
oxygen. Body temperature was maintained by keeping the mice on thermostatted heating
pads. A laparotomy was performed and the bile duct was ligated below the gallbladder.
The duodenum of the experimental mice was injected with 500 l of normal saline
containing 50 µg/ml [3H]rosuvastatin (final specific activity = 23 mCi/mmol) and
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200,000 dpm/ml of inulin [14C]carboxylic acid (2 mCi/gram; Perkin Elmer). After 30
minutes, blood was collected by cardiac puncture. The gallbladder, liver, and entire small
intestine including contents were also collected. The small intestine, plasma (~100 µl),
gallbladder, and liver (200 mg) were solubilized by incubation in Solvable (Perkin
Elmer) at 60C for 2-3 hours. After cooling to room temperature, 30% H2O2 was added
and samples were incubated at room temperature for 15 minutes and then at 60C for 1
hour. Aliquots were then removed, neutralized with 0.5 volumes of glacial acetic acid,
added to 5 ml scintillation cocktail (Research Products International Corp.), and counted
(Beckman Coulter Scintillation Counter model # LS 6500). Inulin [ 14C]carboxylic acid
was used to monitor for leakage and paracellular movement. The amount of inulin
[14C]carboxylic acid associated with the small intestine and contents was similar for the
wild type and Ostα-/- mice.

4.2.10

Statistical analysis

Determination of the statistical differences between various group parameters was
determined using either Student t-test, Mann Whitney U-test or ANOVA, as appropriate.
A p-value <0.05 was considered statistically significant.

4.3

4.3.1

Results

Single nucleotide polymorphisms in OSTα and OSTβ

Two common non-synonymous SNPs have been reported in the dbSNP database and
confirmed by frequency, OSTα c.604G>A (Val202Ile; rs939885) and OSTβ c.362C>T
(Pro121Leu; rs75962063). OSTα c.604G>A is observed with an allelic frequency of
43.5% with marked variation among ethnicities. Whereas 604A is the minor allele in
African Americans (14.2%), it is 604G in Asians (22.2%-33.3%), but both alleles appear
similarly frequent in Caucasians. OSTβ c.362C>T is observed in 1.1% of a population
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with Japanese and Chinese descent. Figure 4.1A shows the predicted membrane
topologies of OSTα and OSTβ and the amino acid positions of both SNPs. Amino acid
alignment of OST orthologs suggests the OSTβ Pro121 but not OSTα Val202 as highly
conserved site among the five assessed species (Figure 4.1B).

4.3.2

Novel drug substrates of OSTαβ and reduced uptake by
protein variants

We first evaluated HeLa cells transiently overexpressing OSTα and OSTβ (wildtype) for
their ability to transport TCA, a known OSTαβ substrate (Figure 4.2A). Only HeLa cells
co-transfected with both, OSTα and OSTβ, were capable of TCA uptake compared to the
transporter lacking vector control (pEF), whereas transfection with OSTα or OSTβ alone
did not differ from vector control. An initial screen of 18 radiolabeled drugs using a
single time point and dose identified several potential novel substrates and further
characterization of their transport properties is shown in Figures 4.2 and 4.3. OSTαβ
transported the chemotherapeutic agent docetaxel as well as the lipid-lowering HMG
reductase inhibitors rosuvastatin and atorvastatin (Figure 4.2A). Interestingly, the
structurally related taxene, paclitaxel, was not transported. Our results also suggest the
anti-inflammatory drug sulfasalazine is a substrate of OSTαβ (2.7-fold greater uptake
than vector control) (Figure S1, Supplemental Information, Appendix A). Since OSTαβ
has been described to mediate bidirectional transport (12), potential substrate efflux was
examined in cells co-transfected with the hepatic bile acid transporter Na+-taurocholate
cotransporting polypeptide (NTCP, gene SLC10A1), which has previously been shown to
mediate efficient rosuvastatin and atorvastatin uptake. As shown in Figure 4.2B, coexpression with OSTαβ decreased the intracellular retention of TCA and rosuvastatin by
96% and 69%, respectively as compared to cells transfected with NTCP alone. However,
significant efflux transport was not observed for atorvastatin.
We then evaluated the functional effect of the two variant proteins on OSTαβ transport
activity (Figure 4.3A) based on two common polymorphisms. TCA uptake, assessed as
intracellular TCA accumulation, was 4.2-fold higher in HeLa cells expressing OSTαβ
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wildtype than vector control (Figure 4.3A). Expression of OSTα Ile202(variant)-OSTβ
and OSTα-OSTβ Leu121(variant) resulted in decreased TCA uptake activity compared to
wildtype, which was statistically significant for the latter OSTβ Leu121. Docetaxel,
rosuvastatin and atorvastatin uptake were 2.5-, 1.8-, and 2.1-fold higher in HeLa cells
expressing wildtype OSTαβ than vector control (Figure 4.3A). Only OSTα-OSTβ
Leu121(variant) showed significantly impaired uptake of docetaxel, and transport of
rosuvastatin and atorvastatin were not significantly decreased versus wildtype for the two
variant proteins.
The concentration-dependent uptake kinetics of TCA transport by OSTαβ variants was
examined next (Figure 4.3B). Both variants, OSTα Val202Ile and OSTβ Pro121Leu,
demonstrated lower Vmax values in comparison to wildtype, whereas Km was not
markedly changed. Intrinsic clearance (Vmax/Km) for TCA transport by OSTαβ
(wildtype), OSTαVal202Ile-OSTβ and OSTα-OSTβPro121Leu was 4.34, 3.89, and 4.07
ml/mg of protein/min, respectively. To determine whether reductions in transport
activities for OSTαβ variants are seen with other substrates than TCA, uptake kinetics
was also assessed using the newly identified drug substrates rosuvastatin and docetaxel
(Figure 4.3B). Interestingly, saturation of rosuvastatin transport by OSTαβ was not
achieved despite concentrations up to 1000 µM. Thus, intrinsic clearance was estimated
by linear regression analysis of substrate concentration and observed uptake rate. The
estimated intrinsic clearance for rosuvastatin was 0.624, 0.480, and 0.326 ml/mg
protein/min

for

OSTαβ,

OSTαVal202Ile-OSTβ

and

OSTα-OSTβPro121Leu,

respectively. Lack of saturation of rosuvastatin transport by OSTαβ may be explained by
low affinity of this substrate. Due to poor solubility, docetaxel could not be studied at
concentrations ≥ 200 µM, and at these concentrations, saturation of OSTαβ transport was
not achieved (data not shown). Overall, our findings suggest a moderate reduction in
intrinsic transport clearance for OSTαVal202Ile and OSTβPro121Leu, independent of the
substrate used.
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4.3.3

OSTβ gene variant with reduced cell surface expression

Reduced transport activity may be the result of changes in expression of a functional
protein or impaired trafficking to the cell surface. Thus cell surface expression of both
variants was studied in comparison to wildtype OSTα and OSTβ in transfected HeLa
cells. As shown in Figure 4.4, coexpression of OSTα (wildtype) with OSTβ Leu121
resulted in a profound decrease in cell surface expression of OSTβ but not OSTα protein.
This may be due to impaired cell surface trafficking of OSTβ in the presence of Leu121.
Interestingly, OSTβ protein expression was also moderately decreased in the total protein
lysate. No differences were observed for coexpressed OSTα Ile202 with OSTβ wildtype.

4.3.4

Identification of inhibitors of OSTαβ function

We further evaluated various anticancer and lipid-lowering drugs for their potential to
inhibit uptake of the prototypic OSTαβ substrate TCA. For this purpose, HeLa cells were
pretreated with the inhibitor-containing medium at 25 µM for 5 min prior to 1 min TCA
uptake (Figure 4.5). Inhibition of TCA uptake was observed after pretreatment with
ezetimibe (65.1%, p<0.05) and its active metabolite ezetimibe glucuronide (62.3%,
p<0.05), as well as sulfasalazine (41.1%, p<0.05) when normalized to TCA uptake
without inhibitor (=100%). Results for the previously reported OSTαβ inhibitor
probenecid did not reach statistical significance (4). Similarly, indomethacin lacked
inhibitory properties at this concentration.

4.3.5

OSTαβ affects rosuvastatin disposition in knockout mice

Like human OSTαβ, co-expression of the mouse orthologues in vitro showed uptake
activity for TCA, rosuvastatin and docetaxel (Figure 4.6A). In order to access the in vivo
relevance of intestinal Ostαβ transport for drug disposition, Ostα-/- mice were
administered rosuvastatin. Plasma and tissue concentrations were assessed 30 min after
duodenal drug administration in comparison to Ostα+/+ mice. A small increase in
rosuvastatin absorption in the Ostα-/- mice was observed. Compared to wildtype mice,
rosuvastatin (% of administered dose) was about 2-fold increased in liver (p=0.039) and
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plasma (p=0.0065), with a trend in the same direction for gallbladder/bile, and in the
opposite direction for small intestine and its contents (Figure 4.6B). Of a given dose, a
total of 83% and 84% was recovered in wildtype and knockout mice, respectively. There
was no difference in intestinal inulin absorption. Almost the entire inulin dose remained
in the lumen, thus excluding potential paracellular leakage (data not shown).

4.3.6

OSTα protein is highly expressed in human intestine but not
detected in liver

Relative quantification of OSTα and OSTβ gene expression confirmed that both genes,
among the evaluated tissues, are highest expressed in ileum with a 6- to 8-fold variability,
respectively, with comparable levels in colon (8-fold and 50-fold variability) but also
duodenum (4-fold and 6-fold variability) (Figure 4.7A). OSTα mRNA was abundant in
human liver with 2-fold lower expression compared to average expression in ileum, and
with 100-fold lower expression in kidney. OSTβ mRNA, on the other hand, was more
abundant in kidney than liver with 8-fold and 60-fold lower levels compared to ileum,
respectively. Average threshold cycles (CT) for detection of OSTα mRNA/ OSTβ mRNA
(N=8) by real-time PCR were 22.7/ 23.8, 23.3/ 25.4, and 23.7/ 25.0 for duodenum, ileum,
and colon, respectively, and 23.3/ 30.3 for liver (pooled sample) and 27.6/ 25.9 for
kidney (N=1). Overall there was a positive correlation of intestinal OSTα expression with
OSTβ (Figure S2, Supplemental Information, Appendix A).

Next we analyzed the protein expression from a subset of 6 subjects using Western blot
analysis. OSTα protein was readily detectable in intestinal biopsies using a rabbit
polyclonal antiserum against the C-terminal portion of OSTα. OSTα appeared as two
bands of 55kDa and 110kDa on Western blots of biopsy samples from duodenum,
terminal ileum and colon (Figure 4.7B). Control samples prepared from HeLa cells overexpressing OSTα and OSTβ showed the smaller band but no larger species of OSTα. The
calculated molecular weight (MW) for OSTα is 37.7kDa (Protein calculator;
http://www.scripps.edu/~cdputnam/protcalc.html), and N-glycosylation of OSTα has
been previously shown to result in the mature 40kDa protein form.(17-18) In addition, a
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partially glycosylated precursor form of ~35kD, and an unglycosylated form of ~31kDa
were described after expression in COS-7 (African green monkey kidney fibroblast cells)
and HepG2 cells (human liver hepatocellular carcinoma cells). Our results suggest that in
the intestine the 55kDa form of the OSTα subunit likely represents a heterodimer of the
mature (or precursor) OSTα with OSTβ, the latter recently reported to form two bands of
~15kDa and ~20kDa size (predicted MW of 14.3kDa) in HepG2 cells (18). On the other
hand, the 110kDa form of the OSTα subunit may suggest formation of heteromultimers
(e.g. OSTα-OSTα-OSTβ) as previously described in mouse ileum (6). This is furthermore
supported by our later experiment using a commercially available anti-human OSTβ
antibody in a subset of intestinal biopsy samples that did not show the 20 kDa OSTβ
form in human intestine but revealed a 55kDa band corresponding to the 55kDa species
of OSTα seen earlier (Figure S3, Supplemental Information, Appendix A). Intestinal
OSTα protein expression (Figure 4.7B) was moderately variable among patients and
interregional differences corresponded largely to the observed gene expression pattern
with maximum levels in ileum. As compared to ileum (N=4), OSTα expression was 1.1fold and 2.3-fold lower in colon (N=4) and duodenum (N=6), respectively (Figure S4,
Supplemental Information, Appendix A), although OSTα protein expression in colon
appeared to exceed the level of the ileum in some individuals (Subjects 7 and 34) (Figure
4.7B, upper panel). Since marked OSTα gene expression had been determined in human
liver, we also attempted to measure OSTα protein levels in liver cell lysates (Figure 4.7B,
lower panel). Unexpectedly, no OSTα protein was detected using 15 µg total protein.
Assuming most carrier proteins can be found at the membrane, liver cell membraneenriched fractions were created and reprobed in comparison to expression in duodenum
and kidney. However no band was detected in hepatic membrane fractions, whereas
kidney revealed the smaller 55kDa form of OSTα.
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Human
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Figure 4.1 Putative secondary structure of OSTα and OSTβ (A) and OSTα and
OSTβ amino acid alignments (B).
(A)

Transmembrane

domains

were

(http://www.enzim.hu/hmmtop/index.html)

predicted
(27-28).

using
The

TMMTop

version

transmembrane

2.0

topology

schematic was rendered using TOPO2 (S.J. Johns and R.C. Speth, transmembrane protein

Fig. 1 Reported
display software, http://www.sacs.ucsf.edu/TOPO/topo.html, unpublished).
non-synonymous amino acid changes are shown in black and synonymous changes in
orange. (B) OSTα and OSTβ amino acid alignments. The deduced amino acid sequences
surrounding the variant for putative OSTα (Val202Ile) and OSTβ (Pro202Leu) relative to
orthologues from mouse, rat, cow and dog. The sequences were aligned using the
program MegAlign (DNAStar) with the ClustalW algorithm. Amino acid identity is
displayed with black shading, and the variant residue is boxed.
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Figure 4.2 Drug uptake and drug efflux after transient expression of human OSTαβ
(wild type) in HeLa cells. (A) Time course of uptake by cells over-expressing OSTα, OSTβ,
OSTα and OSTβ (named OSTαβ), or transporter-lacking vector control (pEF). (B) OSTαβmediated drug efflux assessed at 10 min. Values are expressed as percent of cellular uptake
by NTCP alone (=100% uptake). All values are given as mean ± S.E. ***p < 0.001
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Figure 4.2 Drug uptake and drug efflux after transient expression of human OSTαβ
(wild type) in HeLa cells.
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Figure 4.3 Transient expression of human OSTαβ (wild-type and variants) in HeLa
cells to assess drug uptake and transport kinetics. (A) Uptake by cells over-expressing
OSTα and OSTβ (wild-type), OSTα Ile202 (variant) and OSTβ (wild-type), OSTα (wildtype) and OSTβ Leu121 (variant), or blank vector control (pEF) at 2.5 min (TCA) or 5 min
(all other drugs). Values are expressed as percent of cellular uptake by vector control. All
values are given as mean ± S.E. ***p < 0.001, **p<0.01, *p<0.05. (B) Uptake transport
kinetics of OSTα and OSTβ (wildtype, also reference), OSTα_Ile202 (variant) and OSTβ
(wild-type), as well as OSTα (wild-type) and OSTβ Leu121 (variant) following coexpression in HeLa cells conducted at 1 min (TCA) or 2.5 min at varying concentrations.
Parameters for saturation kinetics (Vmax and Km) for TCA were estimated by nonlinear curve
fitting using Prism (GraphPad Software, Inc., San Diego, CA). Data are expressed as mean ±
S.E
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Figure 4.3 Transient expression of human OSTαβ (wild-type and variants) in HeLa
cells to assess drug uptake and transport kinetics.
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Figure 4.4 Immunoblot of total cell lysate and cell surface protein after transient
expression of wild-type and variant OSTαβ in HeLa cells.
Blots were probed for OSTα, OSTβ, and calnexin and Na-K-ATPase as controls.
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Figure 4.5 Inhibition of OSTαβ-mediated taurocholate uptake by drug compounds.
Transport experiments evaluating inhibition of OSTαβ-mediated uptake were carried out in
HeLa cells after transient over-expression of OSTα and OSTβ (wild-type). Inhibitors (25µM)
were added to cells for 5 min prior to uptake initiation. All experiments were carried out in
duplicate or triplicate on at least 2 to 3 separate experimental days.
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Figure 4.5 Inhibition of OSTαβ-mediated taurocholate uptake by drug compounds.
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Figure 4.6 Drug uptake by mouse Ostαβ after transient expression in HeLa cells
and in situ transport studies using Ostα-/- mice.
(A) Uptake by cells over-expressing mOstαβ assessed at 2.5 min (TCA) or 5 min (other
drugs). Values are expressed as percent of cellular uptake by vector control. (B) Fasted
anesthetized female wildtype and Ostα-/- mice (C57Bl/6 background) wereFig.
administered
6
25 µg (50 µg/ml) [3H]rosuvastatin into the duodenum after ligation of the bile duct. After
30 minutes, animals were sacrificed, and blood and tissues collected. Radioactivity was
determined by liquid scintillation counting (% of administered dose).
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Figure 4.7 Expression of OSTα and OSTβ in intestinal biopsy samples from 8 healthy
patients. (A) OSTα and OSTα gene expression in duodenum, ileum and colon compared
with kidney (N=1) and liver (pooled sample) assessed by relative quantification and
normalized to beta actin. (B) Upper panel (left blot): OSTα protein expression in a subset of
individuals (N=6) in duodenum (D), terminal ileum (TI), and colon (C) assessed by Western
blotting. Upper panel (right blot): HeLa cell over-expressing OSTα and OSTβ (positive
control) and blank vector control (pEF). Lower panel: OSTα protein expression in intestine
(N=3) compared with liver (N=4) and derived membrane-enriched fractions (LM) as well as
kidney (N=1).
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Figure 4.7 Expression of OSTα and OSTβ in intestinal biopsy samples from 8
healthy patients.
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4.4

Discussion

OSTαβ plays a key role in bile acid homeostasis by promoting transport of bile acids
from the intestinal lumen into portal blood. Nevertheless, the identity of xenobiotic
substrates and role of OSTαβ in intestinal drug absorption or enterohepatic cycling
remains largely unexplored. The findings of this study indicate that OSTαβ is capable of
transporting a variety of clinically relevant and structurally divergent drugs such as
docetaxel, rosuvastatin and atorvastatin, and sulfasalazine.
Known endogenous and exogenous substrates of OSTαβ include bile acids, the steroid
hormones estrone-3-sulfate and dehydroepiandrosterone-3-sulfate (DHEAS), the cardiac
glycoside digoxin, and the non-steroidal eicosanoid prostaglandin E2, indicating broader
substrate specificity for this transporter (4-5, 12). Drug substrates may follow similar
absorptive pathways to the one used by bile acids in the human intestine. Whereas
apically positioned efflux carriers of the ATP-binding cassette (ABC) family such as Pglycoprotein (also termed ABCB1), BCRP (Breast cancer resistance protein, also termed
ABCG2) and MRP2 (Multidrug-resistance associated protein, also termed ABCC2) as
well as uptake carriers of the OATP family such as OATP2B1 determine the entrance of
a drug into the enterocyte (19-20), the basolateral localized OSTαβ may facilitate drug
extrusion into the portal circulation. Moreover, drugs or their metabolites, if excreted into
bile, may be reabsorbed in the intestine thus allowing enterohepatic recirculation.
Expression of OSTα and OSTβ mRNA has been previously shown in many human
tissues, and is highest in small intestine, colon, liver as well as kidney (4, 12, 21). In this
study, quantitative analysis of OSTα and OSTβ mRNA in intestinal biopsy samples
confirmed the transporters’ high abundance in small and large intestine with moderate
variability, and suggests a positive correlation between expression of subunits.
Importantly, intestinal OSTα protein expression, determined in a subset of the above
described patients, correlated with OSTα mRNA expression, with highest expression in
ileocytes, followed by colonocytes and duodenal enterocytes. Despite significant mRNA

107

expression, OSTα protein appeared to be undetectable in healthy human liver. Moreover,
although OSTα mRNA in liver exceeded that of kidney many-fold, OSTα protein was
detected in kidney but not liver upon Western blot analysis. Our findings are supported
by previous studies, where OSTα and OSTβ mRNA expression levels were comparable in
human intestine, but many-fold differences were observed between the two subunits in
liver and kidney (4, 22). In human liver, OSTα and OSTβ have been reported to be
expressed at the basolateral membrane of cholangiocytes, and to a lesser extent,
hepatocytes (12). Protein expression, as previously assessed by Western blotting,
revealed low or undetectable levels of both subunits in healthy human liver tissue (23). In
comparison, Ostα and Ostβ mRNA expression was not readily detectable in mouse and
rat liver under basal conditions (12). Despite undetectable protein levels by Western
blotting, Ostα and Ostβ have been identified at the basolateral membrane of mouse and
rat cholangiocytes using immunohistochemistry, but not at the sinusoidal membrane of
hepatocytes (12, 24). Moreover, in rodent and human liver, OSTα/Ostα and OSTβ/Ostβ
expression was significantly induced in response to bile acid feeding or cholestasis (11,
22-24). Induction of Ostα and Ostβ is hereby mediated through activation of the
transcription factor farnesoid X-receptor (FXR) by bile acids, supported by ex-vivo
studies utilizing human ileum biopsies, and hepatoma cells (Huh7 and HepG2) (9, 18).
Taken together, our data indicate that OSTα and OSTβ are highly abundant in human
intestine. In healthy human liver, significant expression of OSTα mRNA was observed,
whereas OSTβ mRNA expression was very low. OSTα protein, on the other hand, was
not detectable in human liver.

Recent studies suggest that coexpression and assembly of both OST subunits into a
complex are required for their trafficking to the plasma membrane and protein stability,
prerequisites for any solute transport. Co-immunoprecipitation of Ostα and Ostβ has been
previously shown in extensive studies using membrane preparations of mouse ileum as
well as in transfected HEK cells (6). Particularly, mouse Ostα was observed as a
predominant protein band of 40kD and 80kDa, and both Ostα forms were found to
interact with Ostβ. Similarly, our findings suggest that OSTα and OSTβ form
heterodimers and heteromultimers in human intestine.
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Preliminary genotyping efforts in our laboratory discovered three common SNPs in OSTα
(rs939885; rs34352044; rs17852687) and none in OSTβ. More recently, large genotyping
projects such as HapMap (http://hapmap.ncbi.nlm.nih.gov/) and the 1000Genomes
project (http://www.1000genomes.org/) have identified many more coding region SNPs
in both genes including deleterious mutations such as frame shifts. However, the majority
of the reported genetic variation lacks information regarding their prevalence. To study
potential consequences of OSTα and OSTβ polymorphisms, we selected two relatively
common non-synonymous SNPs reported in the dbSNP database with confirmed
frequency. Our findings suggest an overall moderate reduction of OSTαβ transport
activity, particularly for the OSTβ 121Leu variant. Decreased OSTβ protein expression
and cell surface trafficking appear to be the underlying mechanisms for the observed
functional effect. Nevertheless, clinical relevance of OSTβ c.362C>T cannot be ruled out.
Interestingly, after duodenal administration, Ostα-/- mice exhibited higher rosuvastatin
concentrations in plasma and liver compared to wildtype mice suggesting increased
intestinal drug absorption due to lack of Ostαβ. This unexpected finding may be the result
of a complex interplay of Ostαβ with other murine intestinal statin transporters (25).
Inhibition of OSTαβ-mediated bile acid efflux from the enterocyte into the portal
circulation may present a potential mechanism of drug-induced intestinal toxicity due to
increased intracellular concentrations of cytotoxic bile acids. Inhibition can occur from
the blood side, or from within the enterocyte. Various drug compounds such as
spironolactone, probenecid, digoxin, as well as indomethacin have been reported to
inhibit OSTαβ-mediated estrone 3-sulfate uptake at relatively high concentrations (200 1000 µM) (4). The current study screened various anticancer and lipid-lowering drugs for
their potential to inhibit uptake of taurocholate, and identified ezetimibe, its active
metabolite ezetimibe glucuronide as well as sulfasalazine as inhibitors at 25 µM, a
concentration very likely achieved in the enterocyte milieu after oral administration. A
well known side-effect of ezetimibe is diarrhea. It is plausible such intestinal side effects
may be exacerbated by inhibition of OSTαβ-mediated intestinal bile acid absorption.
Moreover, intravenously administered substrate drugs of OSTαβ may exhibit their effect

109

from the blood side by competing for OSTαβ transport, for example plasma
concentrations achieved with docetaxel are as high as 7 µM in patients with a 100 mg/m 2
dosing regimen (26).
Accordingly, we propose a potential role for OSTαβ in intestinal drug absorption. We
further propose that inhibition of OSTαβ and subsequent intracellular bile acid
accumulation may be an underappreciated mechanism of drug-induced intestinal toxicity.
However, despite the presence of mRNA, lack of significant OSTα protein in human
livers suggest this transporter is unlikely to play a significant role in hepatic drug
substrate or bile acid transport in healthy individuals. Clinical relevance of OSTα and
OSTβ single nucleotide polymorphisms warrant further studies.
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DRUG TRANSPORTER PHARMACOGENETICS:
IMPLICATION FOR EZETIMIBE DRUG LEVEL3

3

The material in this chapter is based on a manuscript in preparation: Schwarz UI,
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5.1

Introduction

Low-density lipoprotein cholesterol (LDL-C) reduction has been identified as a key
factor in preventing coronary heart disease, particularly in high-risk patients (1). The
level of plasma cholesterol is influenced by de novo biosynthesis but also absorption of
biliary and dietary cholesterol. Ezetimibe is a selective inhibitor of intestinal cholesterol
absorption (2), and reduces LDL-C alone or in combination with 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, also known as statins (34). It presumably acts through inhibition of the Niemann-Pick C1 like 1 Protein
(NPC1L1) (5-6), a specific transporter that facilitates uptake of intestinal cholesterol and
phytosterols into enterocytes (7-8). Currently, the role of ezetimibe on coronary disease
progression and in reducing the residual risk of cardiovascular events after statin
monotherapy remains unknown (9-10). However, ezetimibe has been recommended as a
second- or third-line agent in patients with primary hypercholesterolemia that do not
achieve LDL-C treatment goals due to poor tolerance to statin monotherapy or persistent
elevation of LDL-C despite adequate dosage of statins (1, 10). In addition, it may be a
treatment option in high risk patients and patients with refractory hypercholesterolemia,
i.e. familial hypercholesterolemia or sitosterolemia (11).

After oral dosing, ezetimibe undergoes rapid and almost complete glucuronidation in the
intestinal wall to its active metabolite, ezetimibe glucuronide, which comprises most
(90%) of the drug in human plasma (12). Overall, ezetimibe is well tolerated and has a
good safety and drug interaction profile (13-14). Ezetimibe plasma level is unaffected by
potent inducers or inhibitors of cytochrome P450 enzymes (CYPs), and ezetimibe does
not alter the plasma concentration of co-prescribed drugs metabolized by CYP enzymes
such as warfarin or midazolam (15).

The lipid-lowering response of ezetimibe correlates well with dose and plasma
concentration (15-16). The recommended 10 mg daily dose of ezetimibe results in an
average LDL-C reduction of 20% to 25%, alone or in combination with statins (13, 17-
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19). Nevertheless, marked interpatient variation has been observed with respect to its
LDL-C lowering ranging from no response to a marked decrease of 70% compared to
pretreatment values (14, 20-21). Variability in pharmacodynamic response may be caused
by factors affecting the exposure of the drug (ezetimibe concentration) or factors
affecting the drug target. On the one hand, common haplotypes defined by three common
polymorphisms in the gene encoding the intestinal cholesterol transporter, NPC1L1, have
been reported to determine the LDL-C lowering response to ezetimibe (20). In addition,
two rare NPC1L1 mutations were identified in two non-responders of ezetimibe (21). On
the other hand, recent drug interaction studies suggest potential involvement of
membrane transport proteins affecting the circulating ezetimibe level (22-25). For
example, coadministration of cyclosporine resulted in a significant 3.4-fold increase in
total ezetimibe exposure (26-27). The immunosuppressant is known to inhibit various
membrane carriers, including the drug uptake facilitating liver-specific organic anion
polypeptide (OATP) 1B1 as well as efflux transporters of the ATP-binding cassette
(ABC) family such as ABCC2 and ABCB1 (28-29). Preliminary results from cell-based
studies as well as data from genetically modified mouse models further support the
notion that ezetimibe and/or its glucuronide metabolite are substrates of intestinal and
hepatic drug transporters (30-33). Common genetic polymorphisms in these transport
proteins are known to contribute to interindividual variation in the exposure of a number
of drugs, including other lipid-lowering agents such as statins (34).

Currently, the determinants of variability in the systemic exposure of ezetimibe and
pharmacological responses are not well understood. Our objective was to assess the
interpatient variability in ezetimibe and ezetimibe glucuronide plasma level, and to
characterize the relative importance of uptake and efflux transporter polymorphisms as
well as other clinical and demographic factors in patients with hypercholesterolemia in a
clinic situation. Our results characterize the demographic factors age, body mass index,
and gender as well as concomitant lipid-lowering therapy with fenofibrate as major
predictors of ezetimibe and ezetimibe glucuronide plasma level, whereas drug transporter
genetics plays only a minor role.
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5.2

5.2.1

Methods

Study subjects and design

Patients diagnosed with hyperlipoproteinemia aged 18 years and older who were taking a
stable daily dose of 10 mg or 20 mg ezetimibe (Ezetrol, Merck Frosst/Schering
Pharmaceuticals) were prospectively enrolled in this observational study from August
2009 till May 2011. During a regular clinic visit at the London Health Science Center
(London, Canada), a single venous blood sample was drawn and placed immediately on
ice. After centrifugation of samples, plasma was stored at -80C until analysis of
ezetimibe and ezetimibe glucuronide levels. DNA was isolated from blood to test for
genetic variants. A detailed medical history was obtained, and the time of the last
ezetimibe dose, as reported by the patient, was recorded. Clinical information obtained
included the patient’s age, ethnicity (self-reported), weight, height, smoking status and
alcohol use, as well as past medical history and co-medication. All subjects provided
informed written consent. The study protocol was approved by the Research Ethics Board
of the University of Western Ontario, London, Canada.

5.2.2

DNA extraction and genotyping

Genomic DNA was isolated from blood samples with Gentra Puregene extraction kit
(Qiagen, Alameda, CA, USA), and concentration determined by Quant-iT PicoGreen
dsDNA assay (Invitrogen, Carlsbad, CA, USA). Genotyping of uptake and efflux
transporter polymorphisms was performed by TaqMan Drug Metabolism Genotyping
Assays (Applied Biosystems, Carlsbad, CA, USA), using a 7500 Real-time PCR system
(Applied Biosystems): SLCO1B1 c.388A>G (rs2306283, C__1901697_20); SLCO1B1
c.521T>C

(rs4149056,

C__30633906_10);

SLCO1B3

c.699G>A

(rs7311358,

C__25765587_40); SLCO2B1 c.935G>A (rs12422149, C__3101331_10); ABCB1
c.3435C>T

(rs1045642,

C___7586657_20);

ABCC2

c.1249G>A

(rs2273697,

C__22272980_20); and ABCG2 c.421C>A (rs2231142, C__15854163_70). Genotyping
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of ABCG2 c.34G>A (rs2231137) was determined by a custom TaqMan assay (35) and of
the UGT1A1*28 promotor polymorphism (TA)6>(TA)7 (rs8175347) by a TaqMan 5'nuclease assay (36). Only ABCG2 c.34G>A deviated from Hardy-Weinberg equilibrium.
The allelic frequency of the variant alleles was ≥ 5% for all SNPs evaluated (Table 5.1).

5.2.3

Quantitative analysis of ezetimibe and its glucuronide
metabolite

Ezetimibe, ezetimibe glucuronide, and ezetimibe-d4 were purchased from Toronto
Research Chemicals, North York, Canada. Plasma concentration of ezetimibe and
ezetimibe glucuronide was determined using liquid chromatography-tandem mass
spectrometry (LC-MS/MS). Ezetimibe-d4 was used as internal standard (IS). Briefly, 200
μL of acetonitrile and 5 μL of IS were added to 100 μL of plasma and centrifuged at
14,000 rpm for 20 min. The resulting supernatant was added to 0.05% formic acid in
water (2:3, v/v). Ezetimibe, ezetimibe glucuronide, and IS were separated with a C18
reverse-phase column (Hypersil Gold, 50 x 5 mm, 5 µM particle size; Thermo) using
gradient elution with 0.05% formic acid in water and 0.05% formic acid in acetonitrile
(20% to 70%) in a 10 min run time (TLX2 high performance liquid chromatography
system, Thermo Scientific). The mass spectrometer (TSQ Vantage triple-quadrupole
mass spectrometer, Thermo Scientific, Pittsburgh, PA, USA) was set in negative mode
for detection of ezetimibe, ezetimibe-d4, and ezetimibe glucuronide with transitions of
408  271 m/z, 412  271 m/z, and 584  271, 213, 309, 408 m/z, respectively.
Calibration curves were prepared by spiking blank plasma with known drug
concentrations ranging from 0.1 - 100 ng/mL for ezetimibe and 2.5 - 1000 ng/mL for
ezetimibe glucuronide. The lower limit of quantification was 0.1 ng/mL for ezetimibe and
5 ng/mL for ezetimibe glucuronide. Quality control (QC) samples were prepared at
concentrations of 0.5, 5 and 50 ng/mL for ezetimibe, and 5, 50, and 500 ng/mL for
ezetimibe glucuronide. Three sets of freshly prepared calibration curves and QC were
placed onto each 96 well plate to account for potential changes in ezetimibe glucuronide
concentration. The interday coefficient of variation was 3% and 7%, and accuracy (bias)
6% and 8% for ezetimibe and ezetimibe glucuronide QC samples, respectively.
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5.2.4

Statistical analysis

To examine differences in ezetimibe concentration with respect to each dose,
concomitant medication or genotype group, Mann-Whitney and Kruskal-Wallis tests with
Dunn’s post-test were employed, as appropriate. Spearman's Rank-Order Correlation
analysis of plasma concentration and clinical characteristics was performed. A two-sided
p-value <0.05 was considered significant. To examine the role of transporter
polymorphisms and clinical variables in the prediction of ezetimibe and ezetimibe
glucuronide plasma concentration, multiple linear regression was performed with
inclusion of patients with blood collection times within the linear range of the
pharmacokinetic profile of ezetimibe and its glucuronide metabolite ≥ 6 hr and < 24 hr (N
= 104). Regression analysis of the ezetimibe glucuronide/ ezetimibe ratio included
patients with blood collection times > 0 hr and < 24 hr (N = 152) and linearity was
assumed based on the data. Since the distribution of plasma concentration was skewed,
ezetimibe and ezetimibe glucuronide plasma concentration as well as their ratio were logtransformed prior to analysis. Transporter and enzyme genotypes were represented on a
scale of 0 to 2 according to the number of minor (variant) alleles carried. In our
predominantly Caucasian population, SLCO1B3 c.699A was considered the minor allele
despite its high prevalence. Different genetic models including dominant, co-dominant,
recessive and additive models were considered for each polymorphism and the model that
best described the log-transformed ezetimibe concentration. Multiple R2 values were
normalized by age, body mass index (BMI), gender, ethnicity, dose, and time from last
dose. Final models are adjusted by age, BMI, gender, ethnicity and include explanatory
variables with p-values < 0.05. Statistical analysis was performed using the statistical
software R (http://www.r-project.org/) and GraphPad (GraphPad Software, Inc., San
Diego, CA).
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5.3

5.3.1

Results

Study subjects and demographics

In total, 174 patients on steady-state ezetimibe therapy were enrolled in the study. A total
of 22 patients were excluded from analysis (time from last dose unknown, N = 7; time
from last dose > 24hr, N = 8; alternate dosing, N = 3; drug concentration < LLOQ, N =
4). The remaining 152 predominantly Caucasian patients (61 yrs, 86 kg) were analyzed
and the patients’ baseline characteristics are summarized in Table 5.2. Blood sampling
occurred on average 10.4 hours from the last ezetimibe dose, and in 32% of these patients
(N = 48) within 6 hours. The majority of patients (>90%) received a daily oral dose of 10
mg ezetimibe, and on average 5.4 concomitant medications. Other lipid-lowering agents
were frequently co-prescribed such as statins (80% of patients), fenofibrate (14.5%) or
gemfibrozil (1.3%).

5.3.2

Variability in ezetimibe and ezetimibe glucuronide
concentration in plasma

We observed up to 67-fold variability in plasma ezetimibe concentration and 140-fold
variability in plasma ezetimibe glucuronide concentration among patients on a 10 mg
dose (Figure 5.1). Mean plasma concentrations were about 2-fold higher in patients
taking 20 mg compared to a 10 mg daily dose with 9.1 ng/mL (SD 8.88) and 4.3 ng/mL
(SD 3.14) for ezetimibe (P<0.01), respectively, and 171 ng/mL (SD 113.2) and 74 ng/mL
(SD 86.5) for ezetimibe glucuronide (P<0.001), respectively (Figure 5.1A). Plasma
concentration was associated with sampling time for patients taking a 10 mg dose. In
patients taking 10 mg ezetimibe daily with blood sampling less than 6 hr and ≥ 6 hr to <
24 hr from the last ezetimibe dose, concentrations were 5.2 ng/mL (SD 3.23) and 3.9
ng/mL (SD 3.03) for ezetimibe, and 132 ng/mL (SD 127.8) and 49 ng/mL (SD 40.77) for
the metabolite, respectively (Figure 5.1B).
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5.3.3

Determinants of ezetimibe concentration

In order to assess the association of clinical and pharmacogenetic variables with the
ezetimibe concentration observed, multiple linear regression analysis was performed
(Table 5.3). Only those patients with blood drawn at least 6 hours after their last dose
were included. Multiple regression analysis indicated that plasma ezetimibe concentration
was higher in patients with the reduced-function efflux transporter polymorphism ABCB1
(c.3435T, p=0.005)(37). Among demographic parameters, gender (p<0.001) and BMI
(p=0.035) were associated with plasma ezetimibe concentration, whereas age did not
reach statistical significance (p=0.063). Finally, concomitant treatment with atorvastatin
and rosuvastatin was associated with increase in ezetimibe plasma concentration
(p=0.010 and 0.037, respectively). As expected, ezetimibe concentration was dependent
on dose (p<0.005), and blood sampling time from the last dose taken (p<0.05). Together,
the multiple R2 value of the model was 0.355 (adjusted R2 value 0.286).

Further confirmation of the importance of demographic characteristics was gained from
correlation analysis (Figure 5.2). Ezetimibe concentration correlated significantly with
weight (r = -0.3542; kg), BMI (r = 0.3003; kg/m2), and age (r = 0.3571; years). As well,
females were found to have a 60% higher ezetimibe level compared to males (6.4 versus
3.9 mg/mL, respectively; P = 0.0064).

5.3.4

Determinants of ezetimibe glucuronide concentration

Multiple linear regression analysis (Table 5.4) demonstrated that plasma ezetimibe
glucuronide concentration is highly related to age (p<0.0005). Unexpectedly, there was
no significant contribution of pharmacogenetic markers or concomitant medication to
plasma metabolite concentration. Similar to the parent drug, the glucuronide
concentration was related to dose (p<0.001) and time from the last dose (p<0.010). The
multiple R2 value of this model was 0.266 (adjusted R2 value 0.220). Since only patients
with blood drawn at least 6 hours after their last dose were included, half of 22 patients
on fenofibrate had been excluded from the former analysis applying a cautious approach
with respect to the assumed linearity of the pharmacokinetic profile based on published
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data (15). However, Cmax values for the active metabolite are reported to occur very early,
about 1 to 3 hours after dosing (15). In addition, log transformation of the metabolite
concentration further diminished potential non-linearity within the concentration-time
profile. Accordingly, after inclusion of all patients with a blood sampling time less than
24hr from the last ezetimibe dose, ezetimibe glucuronide concentrations were, in
addition, influenced by concomitant fenofibrate therapy (p=0.007, Table 5.4), which
markedly increased the R2 value of the model to 0.424 (adjusted R2 value 0.392).

Correlation analysis further supported that ezetimibe glucuronide concentration positively
correlated with age (r = 0.4144), but no other demographic variables (Figure 5.2).

UGT1A1 has been reported as the key enzyme mediating the glucuronidation of
ezetimibe to its active metabolite (38). Accordingly, we observed significant correlation
(r = 0.7173) between ezetimibe and ezetimibe glucuronide level in our study population
(Figure 5.3). UGT1A1 has been shown to be polymorphic, and can harbour a common
impaired-function promoter variant, UGT1A1 (TA)6>(TA)7 (also referred to as
UGT1A1*28) (39-40). Patients carrying one or more UGT1A1*28 alleles showed a trend
of lower ezetimibe glucuronide concentration compared to wild type patients (46.6
ng/mL and 64.8 ng/mL, respectively; P = 0.057; Figure 5.3). With other explanatory
variables, regression analysis did not indicate that UGT1A1 *28 is a significant predictor
of ezetimibe glucuronide concentration.

5.3.5

Determinants of ezetimibe glucuronide/ ezetimibe ratio

Metabolite-to-parent ratio is utilized as a metric of transport and/or enzyme activity. To
analyze the ratio, all patients with blood drawn less than 24 hours after their last dose
were included. Multiple regression analysis (Table 5.5) showed that the ezetimibe
glucuronide/ezetimibe ratio was higher in carriers of the reduced-function uptake
transporter polymorphism SLCO1B3 c.699A (p=0.010) (41). Furthermore, the ratio was
dependent on gender (p=0.033), age (p=0.006), and BMI (p=0.002). The multiple R 2
value of this model was 0.352 (adjusted R2 value 0.320).
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As described above, concomitant fenofibrate treatment explained a significant portion of
ezetimibe glucuronide exposure. In patients taking fenofibrate, ezetimibe glucuronide
level was more than two-fold augmented (149.8 ng/mL [SD 162.0]) compared to those
without this comedication (70.9 ng/mL [SD 69.9]), but no difference was observed for
ezetimibe level. As a result, patients with fenofibrate showed a significantly higher
metabolite-to-parent

ratio

than

patients

not

taking

fenofibrate

indicating

a

pharmacokinetic interaction (Figure 5.4).

5.3.6

Ezetimibe trough level

Recently, a trough concentration of greater than 15 ng/mL total ezetimibe (ezetimibe plus
active glucuronide metabolite) has been reported as the required drug concentration to
reach a greater than 15% reduction of LDL-C in patients with primary
hypercholesterolemia (16). The predicted trough plasma concentrations in our data set
based on the respective regression models of 16.7 ng/mL total ezetimibe (ezetimibe plus
ezetimibe glucuronide) represented the lower 25th percentile of patients taking a 10 mg
dose. Accordingly, up to 25% of patients may have a trough level that is inadequate to
achieve more than 15% LDL-C reduction. Patients at risk of suboptimal response may be
identified on the basis of demographic variables as well as fenofibrate use (Figure 5.5).
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Table 5.1 Genotype frequency of patients (N = 152)
Homozygous
Polymorphisms

Wild type carrier

Heterozygous carrier

carrier

MAF

N

(%)

N

(%)

N

(%)

SLCO1B1 388A>G

54

35.5

77

50.7

21

13.8

0.391

SLCO1B1 521T>C

110

72.4

38

25.0

4

2.6

0.151

SLCO1B3 699G>A*

2

1.3

37

24.3

113

74.3

0.865

SLCO2B1 935G>A

121

79.6

31

20.4

0

0.0

0.102

ABCB1 3435C>T

26

17.1

87

57.2

39

25.7

0.543

ABCC2 1249G>A

92

60.5

49

32.2

11

7.2

0.234

ABCG2 421C>A

127

83.6

24

15.8

1

0.7

0.086

ABCG2 34G>A**

138

91.4

11

7.3

2

1.3

0.050

UGT1A1 *1>*28

74

48.7

59

38.8

19

12.5

0.319

MAF, Minor allelic frequency

* decreased-function SLCO1B3 699A allele is more frequent in Caucasians than the
699G allele (wild type)
** not in Hardy-Weinberg equilibrium
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Table 5.2 Patient demographics
Gender, N (%)

Male

104

(68.4)

Female

48

(31.6)

Age, yrs

Mean (SD)

60.9

(10.8)

Ethnicity, N (%)

Caucasian

139

(91.4)

Other

13

(8.6)

Weight, kg

Mean (SD)

85.8

(18.9)

BMI, kg/m2

Mean (SD)

24.9

(5.0)

Blood sample

Hours from last dose

10.4

(5.7)

Dose, N (%)

10mg daily dose

139

(91.4)

20mg daily dose

13

(8.6)

<6hr

48

(31.6)

6hr - 24hr

104

(68.4)

Number of co-medications*

Mean (SD)

5.4

(3.2)

Patients co-prescribed statins, N (%)

Atorvastatin

35

(23.0)

Rosuvastatin

70

(46.1)

Other statins

16

(10.5)

No statin

31

(20.4)

Gemfibrozil

2

(1.3)

Fenofibrate

22

(14.5)

Digoxin

3

(2.0)

125

(82.2)

Time from last dose, N (%)

Patients with interacting drugs, N (%)

None

*excludes vitamin B2, vitamin D, vitamin E, vitamin B6, vitamin C, vitamin B12,
multivitamin, ubiquinone (Co-Enzyme Q10), folic acid, curcumin, Ca2+ supplement,
Mg2+ supplement, ferrous sulfate, omega-3, glucosamine, fish oil, flax seed oil, cod liver,
garlic, gingko biloba, and cranberry
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Table 5.3 Effects of selected predictors on log ezetimibe concentration in linear
regression
Variable

Effect (B)

p value

Gender

-0.543

<0.001

Age

0.011

0.063

BMI

-0.0317

0.035

0.610

0.010

0.449

0.037

0.319

0.005

Atorvastatin co-

R2 value (adjusted)

meds
Rosuvastatin comeds
ABCB1 3435

0.355 (0.286)

Time from last dose (B -0.042) and ezetimibe dose (B 0.082) were significant in this
model.
R2 value was adjusted for age, gender, ethnicity, BMI, dose, and time from last dose.
Plasma concentration determined >/= 6hr and <24hr from last dose
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Table 5.4 Effects of selected predictors on log ezetimibe glucuronide concentration
in linear regression
Variable

Effect (B)

p value

R2 value
(adjusted)

Plasma concentration determined >/= 6hr, <24hr post dose*
Age

0.023

<0.001
0.266 (0.220)

Plasma concentration determined < 24hr post dose**
Age

0.028

<0.001

Fenofibrate

0.488

0.007
0.424 (0.392)

*Time from last dose (B -0.061) and ezetimibe dose (B 0.112) were significant in this
model;
**Time from last dose (B -0.064) and ezetimibe dose (B 0.078) were significant in this
model
R2 value was adjusted for age, gender, ethnicity, BMI, dose, and time from last dose
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Table 5.5 Effects of selected predictors on log ezetimibe glucuronide/ ezetimibe
ratio in linear regression ( < 24hr post dose)
Variable

Effect (B)

p value

Gender

0.235

0.033

Age

0.012

0.008

BMI

0.031

0.002

Fenofibrate

0.471

<0.001

SLCO1B3 699

0.264

0.015

R2 value (adjusted)

0.3516 (0.3201)

Time from last dose (B -0.035) was significant in this model;
R2 value was adjusted for age, gender, ethnicity, BMI, dose, and time from last dose
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Figure 5.4 Plasma concentration and metabolite-to-parent ratio for study patients
(N = 152) receiving fenofibrate in comparison to patients without concomitant
fenofibrate.
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Figure 5.5 Determinants of therapeutic trough level of total ezetimibe (ezetimibe

mean BMI of 24.9 (top panel) and the mean age of 60.9 years (bottom panel). Green
color indicates a trough level ≥ 15 ng/mL, red color indicates a trough level < 15 ng/mL.

133

5.4

Discussion

In the current study, plasma concentration of ezetimibe and ezetimibe glucuronide varied
widely in dyslipidemic patients. Multivariate analysis suggested demographic factors and
concomitant fenofibrate treatment are major determinants of ezetimibe exposure.
Interestingly, an ABCB1 efflux transporter polymorphism explained a small portion of the
observed interpatient variability, whereas impaired-function polymorphisms in the uptake
transporters OATP1B1 and OATP1B3 were not found to be associated with ezetimibe
nor its metabolite concentration.

Polymorphisms in drug transporter genes belonging to the ABC efflux carrier family and
the OATP uptake carrier family have been reported to affect the pharmacokinetics of
many clinically relevant drugs (34). Recent evidence suggests that ezetimibe and its
active metabolite, ezetimibe glucuronide, are subject to active drug transport in the
human intestine and liver (30-33). Our results indicate that the efflux transporter variant
ABCB1 c.3435C>T is a significant predictor of ezetimibe concentration in plasma,
whereas the uptake transporter variant SLCO1B3 c.699G>A is a predictor of the parentto-metabolite ratio but not plasma concentration. Previously, ezetimibe glucuronide was
shown to be a substrate of OATP1B1 but not OATP1B3 in uptake studies using
transfected HEK239 cells, and healthy subjects carrying at least one gain-of-function
allele SLCO1B1*1b differed in plasma levels of ezetimibe glucuronide and ezetimibe,
compared to wild type (30). Preliminary results of our laboratory (unpublished data)
suggest ezetimibe glucuronide is a substrate of OATP1B3, a hepatic carrier that shares
much of the structure and substrate specificity of OATP1B1 (42). Regarding the role of
ABC efflux transporters in ezetimibe exposure, a more than 2-fold higher ezetimibe
glucuronide concentration has been observed in serum and liver of mice lacking Abcb1
compared to wild type, as well as 2-fold higher hepatic ezetimibe levels (31). In addition,
a role of Abcg2, Abcc2 or Abcc3 in the pharmacokinetics of ezetimibe glucuronide has
been established in various models of transporter deficient mice (33). Taken together, our
data suggest that a common genetic polymorphism in the efflux transporter ABCB1 is a
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predictor of ezetimibe concentration, whereas the uptake transporter OATP1B3 variant
explains only the metabolite-to-parent ratio. OATP1B1 was not found to play a role in
our patients.

Fibric acid derivatives such as fenofibrate are lipid-altering medications that effectively
reduce triglycerides and raise HDL-C concentrations in patients with mixed
hyperlipidemia, and are often used as combination therapy (43-44). In the current study,
concomitant fenofibrate therapy has been identified as a key determinant of ezetimibe
glucuronide concentration, resulting in a more than two-fold higher concentration in
fibrate-treated patients compared to patients without this agent. This confirms results of a
smaller randomized trial where the combination of 200 mg of fenofibrate with 10 mg
ezetimibe led to increased exposure of total ezetimibe (ezetimibe plus ezetimibe
glucuronide) and greater LDL-C reductions than ezetimibe alone (23). These findings
suggest a potential clinically significant drug interaction involving a pharmacokinetic
mechanism. Clearance of fenofibrate has been shown to involve glucuronidation (45),
however competition for the same metabolism pathway would be predicted to result in
decreased formation of ezetimibe glucuronide (38). In studies using human hepatocytes,
fibrates have also been reported as weak inducers of UGT1A1, the key enzyme for
ezetimibe glucuronidation (46). Increased UGT1A1 activity may explain the observed
increase in ezetimibe glucuronide level in our patients. On the other hand, cell-based
studies report fenofibrate as an inhibitor of OATP1B1 and ABCB1 transport (47). With
ezetimibe glucuronide as a potential substrate of these carriers (30-31, 33), inhibition of
hepatic OATP1B1-mediated uptake as well as biliary and intestinal drug excretion via
ABCB1 would result in enhanced bioavailability of ezetimibe glucuronide. Accordingly,
our data support that the synergistic lipid-lowering effect of ezetimibe with fenofibrate
may be explained in part by pharmacokinetic processes involving drug transporters, and
enhanced conjugation of ezetimibe. Combination therapy thus offers a therapeutic benefit
particularly for patients with mixed dyslipidemia.

Demographic factors such as age, body weight, ethnicity or gender potentially affect a
drugs' plasma exposure. Previous studies have identified age as a significant predictor of
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total ezetimibe concentration with 43% higher concentrations in elderly patients aged 70
years compared to 50 year old individuals, whereas gender, race, and weight were not
found to be of relevance (16). Our results demonstrate that ezetimibe glucuronide
concentration was significantly affected by age, whereas ezetimibe concentration further
depended on gender and BMI. Aging is known to affect drug disposition and response
(48), which is often related to changes in renal or hepatic drug elimination in the elderly.
Based on early results from small Phase II studies, renal disease has been shown to
moderately enhance ezetimibe and ezetimibe glucuronide exposure by 50%, but no dose
adjustment is currently suggested for renally impaired patients (15). The moderate renal
effect may be explained by a rather small portion (10%) of the drug that is eliminated via
the kidneys (12). On the other hand, even moderate hepatic impairment resulted in a 3.5fold increase in ezetimibe exposure, which was not explained by the extent of ezetimibe
glucuronidation or protein binding (15). The majority of systemically available ezetimibe
is biliary excreted (12). Age-related changes in hepatic elimination may be suspected as
the underlying mechanism of the age effect observed in the current study.

Currently it is unknown if an increase from the recommended 10 mg daily dose to 20 mg
would be beneficial with respect to the LDL-C lowering response. Up to 20 mg,
ezetimibe appears to be a safe and well-tolerated therapeutic agent (14). Doseproportionality has been reported across the clinically relevant exposure range of 5 mg to
20 mg, that is, if the dose is doubled, concentration will approximately increase by a
factor of two (15-16). Accordingly, our results demonstrate 2-fold higher ezetimibe and
metabolite concentrations in patients on 20 mg ezetimibe daily compared to 10 mg.
Ezetimibe trough level has been observed to correlate well with ezetimibe exposure (16),
and dose and concentration, either alone or together, were shown to correlate
significantly with LDL-C reduction up to a daily dose of 10 mg. Results from Phase II
and III clinical studies do not provide evidence for a further benefit of higher doses
(NDA review Zetia: Clinical pharmacology and biopharmaceutics review, drug
approval). On the other hand, based on regression analysis from these trials a trough
concentration of at least 15 ng/mL total ezetimibe has been proposed to be required to
achieve a greater than 15% reduction in LDL cholesterol (16). However, 27% of patients
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taking a daily dose of 10 mg ezetimibe were reported to not achieve such trough level.
Moreover, based on the predicted trough level of total ezetimibe our data suggest that up
to 25% of patients treated with a daily dose of 10 mg ezetimibe might be just at or below
the recommended therapeutic trough concentration and thus may not benefit from
maximal LDL-lowering response.

The knowledge of key determinants of circulating ezetimibe level can aid in the
prediction of patients that might not reach the therapeutically optimal plasma
concentration. Importantly, the current study identified patient demographics and
concomitant medication such as fenofibrate and statins as well as a genetic marker in a
drug efflux transporter gene as predictors of ezetimibe and ezetimibe glucuronide level
explaining 29% and 39%, respectively, of the observed variability in patients with
hypercholesterolemia. This study indicates that for a majority of patients, optimal
ezetimibe plasma exposure is achieved with a 10 mg daily dose. However, in certain
cases, 20 mg ezetimibe daily may provide additional beneficial effects. Nevertheless,
more studies are needed to provide evidence supporting the pharmacological benefit of
such dose increase.

5.5

1.

References

Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A,
Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau
DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A,
Stone JA, Ur E. 2009. 2009 Canadian Cardiovascular Society/Canadian
guidelines for the diagnosis and treatment of dyslipidemia and prevention of
cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 25:
567-79

137

2.

Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I,
von Bergmann K. 2002. Inhibition of intestinal cholesterol absorption by
ezetimibe in humans. Circulation 106: 1943-8

3.

Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. 2004. Efficacy and safety
of ezetimibe coadministered with simvastatin in patients with primary
hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo
Clin Proc 79: 620-9

4.

Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP,
Suresh R, Yang B, Veltri EP. 2003. Effects of ezetimibe, a new cholesterol
absorption

inhibitor,

on

plasma

lipids

in

patients

with

primary

hypercholesterolemia. Eur Heart J 24: 729-41
5.

Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona
JH, Davis HR, Jr., Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre
DE, Ogawa A, O'Neill K A, Iyer SP, Shevell DE, Smith MM, Tang YS,
Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA.
2005. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl
Acad Sci U S A 102: 8132-7

6.

Hawes BE, O'Neill K A, Yao X, Crona JH, Davis HR, Jr., Graziano MP, Altmann
SW. 2007. In vivo responsiveness to ezetimibe correlates with niemann-pick C1
like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1
orthologs. Mol Pharmacol 71: 19-29

7.

Altmann SW, Davis HR, Jr., Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP,
Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. 2004.
Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption.
Science 303: 1201-4

8.

Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. 2005. Inactivation of
NPC1L1 causes multiple lipid transport defects and protects against diet-induced
hypercholesterolemia. J Biol Chem 280: 12710-20

138

9.

Ansell BJ. 2009. A review of trials evaluating nonstatin lipid-lowering therapies.
Curr Atheroscler Rep 11: 64-6

10.

Al Badarin FJ, Kullo IJ, Kopecky SL, Thomas RJ. 2009. Impact of ezetimibe on
atherosclerosis: is the jury still out? Mayo Clin Proc 84: 353-61

11.

Bruckert E, Giral P, Tellier P. 2003. Perspectives in cholesterol-lowering therapy:
the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption.
Circulation 107: 3124-8

12.

Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, Statkevich
P, Iannucci R, Chowdhury S, Affrime M, Cayen MN. 2002. Disposition of the
selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug
Metab Dispos 30: 430-7

13.

Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP. 2003.
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary
hypercholesterolaemia: a pooled analysis from two controlled phase III clinical
studies. Int J Clin Pract 57: 363-8

14.

Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp
RH, Lipka LJ, Lebeaut AP, Yang B, Mellars LE, Cuffie-Jackson C, Veltri EP.
2001. Effectiveness and tolerability of ezetimibe in patients with primary
hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 23:
1209-30

15.

Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton
KB. 2005. Ezetimibe: a review of its metabolism, pharmacokinetics and drug
interactions. Clin Pharmacokinet 44: 467-94

16.

Ezzet F, Wexler D, Statkevich P, Kosoglou T, Patrick J, Lipka L, Mellars L,
Veltri E, Batra V. 2001. The plasma concentration and LDL-C relationship in
patients receiving ezetimibe. J Clin Pharmacol 41: 943-9

139

17.

Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L, Strony
J, Suresh R, Veltri E. 2004. Efficacy and safety of ezetimibe coadministered with
statins: randomised, placebo-controlled, blinded experience in 2382 patients with
primary hypercholesterolemia. Int J Clin Pract 58: 746-55

18.

Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R,
Maccubbin D, Veltri E. 2004. Achieving lipoprotein goals in patients at high risk
with severe hypercholesterolemia: efficacy and safety of ezetimibe coadministered with atorvastatin. Am Heart J 148: 447-55

19.

Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J.
2005. A community-based, randomized trial of ezetimibe added to statin therapy
to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic
patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin
Proc 80: 587-95

20.

Hegele RA, Guy J, Ban MR, Wang J. 2005. NPC1L1 haplotype is associated with
inter-individual variation in plasma low-density lipoprotein response to ezetimibe.
Lipids Health Dis 4: 16

21.

Wang J, Williams CM, Hegele RA. 2005. Compound heterozygosity for two nonsynonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin
Genet 67: 175-7

22.

Oswald S, Giessmann T, Luetjohann D, Wegner D, Rosskopf D, Weitschies W,
Siegmund W. 2006. Disposition and sterol-lowering effect of ezetimibe are
influenced by single-dose coadministration of rifampin, an inhibitor of multidrug
transport proteins. Clin Pharmacol Ther 80: 477-85

23.

Kosoglou T, Statkevich P, Fruchart JC, Pember LJ, Reyderman L, Cutler DL,
Guillaume M, Maxwell SE, Veltri EP. 2004. Pharmacodynamic and
pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res
Opin 20: 1197-207

140

24.

Gustavson LE, Schweitzer SM, Burt DA, Achari R, Rieser MJ, Edeki T, Chira T,
Yannicelli HD, Kelly MT. 2006. Evaluation of the potential for pharmacokinetic
interaction between fenofibrate and ezetimibe: A phase I, open-label, multipledose, three-period crossover study in healthy subjects. Clin Ther 28: 373-87

25.

Reyderman L, Kosoglou T, Statkevich P, Pember L, Boutros T, Maxwell SE,
Affrime M, Batra V. 2004. Assessment of a multiple-dose drug interaction
between ezetimibe, a novel selective cholesterol absorption inhibitor and
gemfibrozil. Int J Clin Pharmacol Ther 42: 512-8

26.

Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich
P, Kosoglou T, Greenberg HE, Kraft WK, Frick G, Murphy G, Gottesdiener K,
Paolini JF. 2006. Effects of ezetimibe on cyclosporine pharmacokinetics in
healthy subjects. J Clin Pharmacol 46: 321-7

27.

Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich
P, Maxwell SE, Kosoglou T, Murphy G, Gottesdiener K, Robson R, Paolini JF.
2006. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal
transplant patients. J Clin Pharmacol 46: 328-36

28.

Amundsen R, Christensen H, Zabihyan B, Asberg A. 2010. Cyclosporine A, but
not tacrolimus, shows relevant inhibition of organic anion-transporting protein
1B1-mediated transport of atorvastatin. Drug Metab Dispos 38: 1499-504

29.

Kim RB. 2002. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug
Metab Rev 34: 47-54

30.

Oswald S, Konig J, Lutjohann D, Giessmann T, Kroemer HK, Rimmbach C,
Rosskopf D, Fromm MF, Siegmund W. 2008. Disposition of ezetimibe is
influenced by polymorphisms of the hepatic uptake carrier OATP1B1.
Pharmacogenet Genomics 18: 559-68

31.

Oswald S, Koll C, Siegmund W. 2007. Disposition of the cholesterol absorption
inhibitor ezetimibe in mdr1a/b (-/-) mice. J Pharm Sci 96: 3478-84

141

32.

Oswald S, Westrup S, Grube M, Kroemer HK, Weitschies W, Siegmund W.
2006. Disposition and sterol-lowering effect of ezetimibe in multidrug resistanceassociated protein 2-deficient rats. J Pharmacol Exp Ther 318: 1293-9

33.

de Waart DR, Vlaming ML, Kunne C, Schinkel AH, Oude Elferink RP. 2009.
Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and
abcg2. Drug Metab Dispos 37: 1698-702

34.

Degorter MK, Xia CQ, Yang JJ, Kim RB. 2012. Drug transporters in drug
efficacy and toxicity. Annu Rev Pharmacol Toxicol 52: 249-73

35.

Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H,
Palandra J, Gregor JC, Dresser GK, Kim RB. 2008. Breast cancer resistance
protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and
sulfasalazine as an in vivo probe. Pharmacogenet Genomics 18: 439-48

36.

Ehmer U, Lankisch TO, Erichsen TJ, Kalthoff S, Freiberg N, Wehmeier M,
Manns MP, Strassburg CP. 2008. Rapid allelic discrimination by TaqMan PCR
for the detection of the Gilbert's syndrome marker UGT1A1*28. J Mol Diagn 10:
549-52

37.

Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV,
Gottesman MM. 2007. A "silent" polymorphism in the MDR1 gene changes
substrate specificity. Science 315: 525-8

38.

Miller DB, Spence JD. 1998. Clinical pharmacokinetics of fibric acid derivatives
(fibrates). Clin Pharmacokinet 34: 155-62

39.

Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout
D, Tytgat GN, Jansen PL, Oude Elferink RP, et al. 1995. The genetic basis of the
reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's
syndrome. N Engl J Med 333: 1171-5

142

40.

Beutler E, Gelbart T, Demina A. 1998. Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for
regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 95: 8170-4

41.

Letschert K, Keppler D, Konig J. 2004. Mutations in the SLCO1B3 gene affecting
the substrate specificity of the hepatocellular uptake transporter OATP1B3
(OATP8). Pharmacogenetics 14: 441-52

42.

Hagenbuch B, Meier PJ. 2004. Organic anion transporting polypeptides of the
OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily,
new nomenclature and molecular/functional properties. Pflugers Arch 447: 65365

43.

Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy
SM. 2003. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day)
in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol
91: 956-60

44.

Despres JP. 2001. Increasing high-density lipoprotein cholesterol: an update on
fenofibrate. Am J Cardiol 88: 30N-6N

45.

Tojcic J, Benoit-Biancamano MO, Court MH, Straka RJ, Caron P, Guillemette C.
2009.

In

vitro

glucuronidation

of

fenofibric

acid

by human

UDP-

glucuronosyltransferases and liver microsomes. Drug Metab Dispos 37: 2236-43
46.

Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li C,
Eisenhandler R, Carlini EJ. 2005. Comparative effects of fibrates on drug
metabolizing enzymes in human hepatocytes. Pharm Res 22: 71-8

47.

Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M,
Demartis A, Laufer R, Hochman JH, Prueksaritanont T, Lin JH. 2005. Effects of
fibrates on human organic anion-transporting polypeptide 1B1-, multidrug
resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 35: 73753

143

48.

Sitar DS. 2007. Aging issues in drug disposition and efficacy. Proc West
Pharmacol Soc 50: 16-20

144

6

DISCUSSION AND CONCLUSIONS

145

6.1

6.1.1

Summary and discussion

Chapter three

In specific aim 1 we hypothesized that novel loss-of-function polymorphisms in organic
anion transporting polypeptide (OATP) 1B3 exist and that they affect the intracellular
uptake of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
rosuvastatin and atorvastatin, two known OATP1B3 substrates, in a cell-based activity
assay.

As outlined in chapter 3, our data support the above hypothesis. We identified four novel
non-synonymous polymorphisms within the SLCO1B3 coding region. Specifically,
OATP1B3 His520Pro and Val560Ala exhibited markedly lower uptake activity for
rosuvastatin compared to wild type when studied in HeLa cells, however atorvastatin
uptake was not altered. Transport kinetics of the OATP1B3 specific substrate CCK8 and
cell surface expression studies suggested that the observed alterations in transport activity
for His520Pro and Val560Ala, in part, may be explained by reduced total protein
expression and, in some cases, cell surface trafficking.

Previously, polymorphisms of the SLCO1B1 gene encoding the closely related liverspecific uptake transporter OATP1B1 were identified with significant loss-of-transport
activity (1). Among those, the extensively studied SLCO1B1 variant c.521C>T (V174A)
was shown to be associated with increased plasma levels of various statins, including
rosuvastatin, atorvastatin and pravastatin (2-3). Given that many drug substrates of
OATP1B1 are also shared substrates of OATP1B3 including rosuvastatin and
atorvastatin, genetic variation in SLCO1B3 is likely one of the determinants of statin
disposition in patients.

This study suggests substrate-specific effects since the here identified amino acid
substitutions alter transport activity only for some but not all OATP1B3 substrates.
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Similarly, the previously reported SLCO1B3 variants Met233Ile and Ser112Ala resulted
in increased, reduced or unaffected uptake activity for various endogenous as well as
drug substrates of OATP1B3 (4), such as testosterone, paclitaxel and mycophenolic acid
(5-7). Notably, the loss-of-function Val560Ala substitution is localized to the
transmembrane domain 10 of OATP1B3, a region previously characterized as being
critical for substrate specificity (8). When mapped onto a model of OATP1B3 (9), the
side chain of the Val560 residue faces the putative central pore, providing new and
important evidence that the central pore, particularly the C-terminal region of the
transmembrane domain 10, is most likely of functional relevance for OATP1B3.

6.1.2

Chapter four

In specific aim 2 our overall hypothesis was that the organic solute transporter (OST) αβ
is a transporter of important relevance to intestinal absorption of drugs including lipidlowering agents.
First, we hypothesized that OSTβ transports drugs.
In chapter 4, we showed that the bile acid transporter OSTβ is also capable of drug
transport in vitro, supporting our hypothesis. We identified four clinically relevant
therapeutics as novel drug substrates of OSTαβ, the HMG-CoA reductase inhibitors
rosuvastatin and atorvastatin, the chemotherapeutic docetaxel, and the anti-inflammatory
agent sulfasalzine.
OSTαβ has been shown to be highly expressed in human ileum and plays a key role in
bile acid homeostasis by promoting transport of bile acids from the intestinal lumen into
portal blood. Nevertheless, xenobiotic substrates are largely unexplored and the role of
OSTαβ in intestinal drug absorption or enterohepatic cycling remains unknown.
Previously only one drug substrate of OSTαβ had been reported, the cardiac glycoside
digoxin (10-11). Findings of this study indicate that OSTαβ is a capable of transporting a
variety of clinically relevant and structurally divergent drugs including the lipid-altering
agents rosuvastatin and atorvastatin.
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Second, we hypothesized that there is considerable OST and OSTβ expression along the
small and large intestine in humans with high interindividual variability.
In chapter 4, we demonstrated that OSTα and OSTβ are abundant in human small
intestine and colon, data that support our hypothesis. However, we observed only
moderate intersubject variability. Relative quantification of OSTα and OSTβ gene
expression confirmed that both genes show highest expression in ileum with a 6- to 8fold variability, respectively, with similar levels in colon (8-fold and 50-fold variability)
but also duodenum (4-fold and 6-fold variability). There was a positive correlation of
intestinal OSTα gene expression with OSTβ.
OSTα protein was readily detected in intestinal biopsies, and appeared as two bands of
55kDa and 110kDa on Western blots of biopsy samples from duodenum, terminal
ileum and colon. Intestinal OSTα protein expression appeared moderately variable among
patients, and interregional differences corresponded largely to the observed gene
expression pattern with maximum levels in ileum. In a subset of intestinal biopsy samples
evaluated for OSTβ protein expression, we did not observe the expected 20 kDa OSTβ
form previously described but revealed a 55kDa band corresponding to the 55kDa species
of OSTα seen earlier, suggesting the formation of OSTα-OSTβ heterodimers in human
gut. Most recent results have demonstrated that the Ostβ subunit is required for
heterodimerization, proper trafficking of the Ostα-Ostβ complex but also formation of the
functional transport unit (12).
Third, we hypothesized that there are genetic polymorphisms in OSTα and OSTβ genes
with functional impact.
In chapter 4, we described that a common genetic variant in OSTβ, namely c.362C>T
(Pro121Leu), resulted in impaired transport activity after transient expression in HeLa
cells using various drug substrates including rosuvastatin. Decreased intrinsic transport
clearance for OSTβ 121Leu and reduced cell surface expression suggested cell surface
trafficking as a potential underlying mechanism for the observed functional effect. This
data supports our hypothesis. Most recent in vitro findings propose residues within the N-
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terminus and the transmembrane region of mouse Ostβ as key regions for the interaction
with OSTα and for transport activity (12). Our results furthermore suggest functional
importance of the Pro121 residue within the C-terminus of OSTβ.
Four, we hypothesized that there is in vivo relevance of intestinal OSTβ transport for
drug disposition.
In order to evaluate its role in vivo, we have utilized a mouse model. As described in
chapter 4, we observed a higher rosuvastatin concentration in plasma and liver of
transporter lacking animals (Ostα-/-) relative to wild type after duodenal administration,
corresponding to enhanced intestinal absorption. This observation supports a role of
OSTαβ in rosuvastatin disposition in vivo, however decreased intestinal absorption had
been anticipated. So unexpected, this finding may be the result of a complex interplay of
Ostαβ with other murine intestinal statin transporters such as Abcg2 (13).

6.1.3

Chapter five

In specific aim 3 we hypothesized that common polymorphisms of uptake and efflux
transporters located in the human intestine and liver determine interpatient variability in
the systemic exposure of ezetimibe and its active metabolite, ezetimibe glucuronide.

As elucidated in chapter 5, plasma concentration of ezetimibe and ezetimibe glucuronide
varied widely in dyslipidemic patients. Multivariate analysis indicated demographic
factors and co-medication as major determinants of ezetimibe exposure, whereas the
efflux transporter polymorphism ABCB1 c.3435 C>T explained only a small portion of
the observed ezetimibe variability. Furthermore, the uptake transporter polymorphism
SLCO1B3 c.699G>A was identified as a significant variable in the prediction of the
metabolite-to-parent ratio, supporting a role of this transporter in hepatic uptake of
ezetimibe. However, the selected genetic marker did not explain ezetimibe glucuronide
nor ezetimibe plasma concentration in patients. Thus, our results refute the hypothesis.
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6.2

6.2.1

Therapeutic implications and future directions

Chapter three

Most recent findings derived from a prospective clinical study conducted in our
laboratory have demonstrated that genetic variation in the hepatic transporter OATP1B1
but not OATP1B3 is a major determinant of interpatient variability in rosuvastatin and
atorvastatin drug exposure. Nevertheless, these results may be limited by the relatively
small patient numbers and inclusion of patients with predominantly Caucasian descent,
allowing only assessment of the very common modest-effect variant SLCO1B3
c.699G>A (Met233Ile). Thus, the SLCO1B3 c.1679T>C (Val560Ala) variant identified
and shown to have an allelic frequency of 3.6% in African-Americans in this study may
be an important loss-of-function polymorphism with the potential to affect substrate drug
disposition in vivo. However, larger multi-ethnic clinical studies will be required to
understand the overall clinical significance of this finding.

Large genotyping projects such as the HapMap and the 1000Genomes projects and
ongoing research efforts are expected to identify more genetic variants in drug transporter
genes including single nucleotide polymorphisms (SNPs) and larger structural variants
such as deletions and copy number variation. For example, very recently an autosomal
recessive disorder called Rotor syndrome (14), was linked to mutations in SLCO1B3 and
SLCO1B1 genes. This disorder is characterized by conjugated hyperbilirubinemia. The
discovered null mutations resulted in complete and simultaneous deficiencies of the
encoded hepatic transporters, OATP1B3 and OATP1B1, causing interruption of
conjugated bilirubin reuptake into the liver. These mutations, even so rare, are also likely
to alter the in vivo exposure of clinically relevant drug substrates such as statins in
affected patients.
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6.2.2

Chapter four

Based on its abundant expression in human intestine and newly discovered drug
substrates, we propose OSTαβ as an intestinal transporter with broad substrate specificity
for the movement of drugs from the enterocyte to the portal circulation. Drug substrates
may follow a similar pathway to the one used by bile acids in the human intestine. In
concert with other membrane carriers localized to the apical side, the basolateral OSTαβ
may facilitate drug export into the portal circulation, and thus affect drug exposure. Using
rosuvastatin as a probe drug, results from Ostαβ deficient animals suggest an in vivo role
of Ostαβ for drug disposition. Like many other drug transporters, OSTα and OSTβ were
found to be polymorphic, and functional gene variants were characterized. At this point
we may speculate that known and yet unidentified polymorphisms affect drug exposure
in humans. Nevertheless, clinical relevance of OSTα and OSTβ SNPs warrant further
studies.
Recent findings including our own suggest that co-expression and assembly of Ostα and
Ostβ into a complex is required for their trafficking to the plasma membrane and protein
stability, as well as solute transport (12, 15). Our findings in human intestine suggest the
formation of heterodimers (OSTα-OSTβ) and even heteromultimers (OSTα-OSTαOSTβ). Cellular trafficking of both subunits and their interaction has been extensively
studied, however the stoichiometry of the OSTαβ transporter, particularly at the plasma
membrane, is still unknown. Focused proteomics has been recently used to quantify
various membrane transporters using LC-MS/MS analysis, where multiple reaction
monitoring (MRM) is applied (16-17). We have preliminary data showing feasibility of
application of LC-MS/MS to most accurately quantify OSTα and OSTβ protein in cellbased samples over-expressing both subunits as well as human intestine.

6.2.3

Chapter five

Recently, a trough concentration of at least 15 ng/mL total ezetimibe (ezetimibe plus
ezetimibe glucuronide) has been reported as the required drug level to reach a greater
than 15% reduction of LDL-C in patients with primary hypercholesterolemia (18).
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However, 27% of patients enrolled in these studies taking a daily dose of 10 mg
ezetimibe did not achieve such trough level. The predicted trough plasma concentrations
in our data set based on the respective regression models of 16.7 ng/mL total ezetimibe
(ezetimibe plus ezetimibe glucuronide) represented the lower 25th percentile of patients
taking a 10 mg dose. Accordingly, up to 25% of patients treated with a daily dose of 10
mg ezetimibe might be just at or below the recommended therapeutic trough
concentration and thus may not benefit from maximal LDL-lowering response.

Overall, this study indicates that for a majority of patients, optimal ezetimibe plasma
exposure is achieved with a 10 mg daily dose. However, patients at risk of suboptimal
response may be identified on the basis of demographic variables as well as fenofibrate
use. In certain cases, 20 mg ezetimibe daily may provide additional beneficial effects.
Nevertheless, more studies are needed to provide evidence supporting the
pharmacological benefit of such dose increase.

Drug transporters are widely acknowledged as important determinants of drug
disposition, influencing absorption, excretion, and, in many cases, extent of drug entry
into target organs (19). Transporter polymorphisms contribute to interindividual
variability in the exposure of drugs, but may also affect their efficacy and/or toxicity. Our
results suggest highly variable systemic exposure of the lipid-altering agent ezetimibe,
which was explained in part by clinical and pharmacogenetic factors. However it is still
unclear how differences in circulating plasma concentration contribute to the drugs' large
variability in lipid-lowering outcomes (20). In order to further elucidate the association of
plasma concentration with pharmacological response, the assessment of plasma sitosterol
and campesterol, two phytosterols transported by the cholesterol transporter NPC1L1,
may be informative as they are used as surrogate markers of ezetimibe function in vivo.
Furthermore, previously determined NPC1L1 haplotypes reported to determine ezetimibe
response (20), may be meaningful as well. Preliminary results in our laboratory show
feasibility in the measurement of sitosterol in patient plasma using LC-MS/MS analysis.
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6.3

Conclusions

Membrane transporters are increasingly recognized as determinants of drug disposition,
and control the effects and toxicity of drugs. The focus of this thesis was to study the role
of two carriers, OATP1B3 and OSTαβ, as determinants of intestinal absorption and
hepatic entry of lipid-altering drugs both in vitro and in vivo. The uptake transporter
OATP1B3, abundantly expressed in human liver, belongs to an important subfamily of
OATPs with broad substrate specificity. The heteromeric transporter OSTαβ is highly
expressed in human ileum, and is crucial in the enterohepatic circulation of bile acids.

The first part of this thesis examined the influence of genetic polymorphisms of
OATP1B3 on in vitro transport of lipid-lowering drugs. We identified novel proteinaltering variants in the SLCO1B3 gene with impaired-transport activity for the HMGCoA reductase inhibitor rosuvastatin, and characterized molecular determinants of altered
OATP1B3 function. Notably, transport-deficient polymorphisms in OATP1B3 are yet
unrecognized with respect to their potential to affect exposure of drug substrates in vivo.
The second part of the thesis characterized the bile acid carrier OSTαβ as an intestinal
transporter with broad drug substrate specificity of relevance for the movement of
xenobiotics from the enterocyte to the portal circulation. We discovered novel drug
substrates, showed abundant expression in human intestine, and characterized a nonsynonymous OSTβ variant with impaired transport in vitro. We further demonstrated a
potential in vivo effect for rosuvastatin disposition in an Ostα-/- mouse model. Future
studies are warranted to determine the clinical relevance of OSTα and OSTβ
polymorphisms with respect to drug exposure in humans. Lastly, we examined the role of
drug transporter pharmacogenetics on ezetimibe and ezetimibe glucuronide plasma levels
in 152 patients. We identified age, BMI, gender and concomitant fenofibrate use as major
determinants of ezetimibe exposure, whereas transporter polymorphisms were less
important predictors. Taken together, these findings illustrate the contribution of hepatic
and intestinal membrane transporters as well as clinical factors to the observed variability
of drug substrate exposure, and possibly clinical response. Moreover, these transporters

